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Summary of findings {#CD010678-sec-0023}
===================

###### 'Summary of findings\' table 1

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ -------------------------------------- ---------------------------------------- --------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Artemether compared with quinine for treating children with severe malaria**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  **Patient or population:** children with severe malaria  **Settings:** malaria‐endemic countries  **Intervention:** intramuscular artemether  **Comparison:** intravenous or intramuscular quinine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **Illustrative comparative risks\* (95% CI)**                                                 **Relative effect  (95% CI)**                                                                                      **Number of participants  (trials)**   **Certainty of the evidence  (GRADE)**   **Comments**                            

  **Risk with quinine**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **Risk with artemether**                                                                                                                                                                                                                                                                                                                 

  Death                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **151 per 1000**                                                                              **147 per 1000**  (116 to 183)                                                                                     **RR 0.97**   (0.77 to 1.21)           1659  (13 trials)                        ⊕⊕⊕⊝  MODERATE^a,b,c,d^\                Artemether probably makes little or no difference to death compared to quinine.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Due to imprecision                      

  Coma resolution time                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       The mean coma resolution time ranged across control groups from  **17.4 to 42.4 hours**       The mean coma resolution time in the intervention groups was  **5.45 hours shorter**  (7.90 to 3.00 shorter)       ‐                                      358  (6 trials)                          ⊕⊕⊝⊝  LOW^c,e,f,g^\                     Artemether may reduce coma resolution time compared to quinine.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Due to risk of bias                     

  Neurological sequelae at discharge                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         **220 per 1000**                                                                              **185 per 1000**  (145 to 235)                                                                                     **RR 0.84**   (0.66 to 1.07)           968  (7 trials)                          ⊕⊕⊝⊝  LOW^a,b,c,h^\                     Artemether may lead to fewer episodes of neurological sequelae. However, the effects of artemether vary and it is possible that artemether may lead to more neurological sequelae
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Due to imprecision                      

  Parasite clearance time                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    The mean parasite clearance time ranged across control groups from  **22.4 to 61.25 hours**   The mean parasite clearance time in the intervention groups was  **9.03 hours shorter**  (11.43 to 6.63 shorter)   ‐                                      420  (7 trials)                          ⊕⊕⊕⊝  MODERATE^a,c,g,i^\                Artemether probably reduces parasite clearance time compared to quinine.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Due to inconsistency                    

  Fever clearance time                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       The mean fever clearance time ranged across control groups from  **18 to 61.25 hours**        The mean fever clearance time in the intervention groups was  **3.73 shorter**  (6.55 to 0.92 shorter)             ‐                                      457  (8 trials)                          ⊕⊕⊝⊝  LOW^c,j,k,l^\                     Artemether may reduce fever clearance time compared to quinine.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Due to risk of bias and inconsistency   

  \*The **assumed risk** is the median control group risk across studies. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **Abbreviations: CI:** confidence interval; **RR:** risk ratio.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  **GRADE Working Group grades of evidence**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect  **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different  **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect  **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect                                                                                                                                                                                                                                                                                                                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ -------------------------------------- ---------------------------------------- --------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^No serious risk of bias: trials were variable in their risk of bias, but exclusion of the trials at high or unclear risk of selection bias did not change this result.  ^b^No serious inconsistency: none of the individual trials found statistically significant effects, and there was no statistical heterogeneity between trials.  ^c^No serious indirectness: trials were from West Africa, East Africa, Central Africa and one from India. All were in children with severe malaria (aged under 15 years), and most compared the standard dose of intramuscular artemether with the WHO recommended dose of intravenous quinine.  ^d^Downgraded by 1 for serious imprecision: these trials, and the overall meta‐analysis are underpowered to detect a difference or to prove equivalence.  ^e^Downgraded by 2 for serious risk of bias: four of the six trials were at unclear risk of selection bias. When these four trials are excluded the result becomes non‐significant.  ^f^No serious inconsistency: statistically significant differences were only seen in two of the six trials. However, statistical heterogeneity between trials was low and the overall meta‐analysis is statistically significant.  ^g^No serious imprecision: the result is statistically significant and the overall meta‐analysis is adequately powered to detect this effect.  ^h^Downgraded by 2 for very serious imprecision: these trials, and the overall meta‐analysis are underpowered to detect a difference or to prove equivalence. The 95% CI is very wide and includes clinically important differences and no effect.  ^i^Downgraded by 1 for serious inconsistency: the mean difference in parasite clearance time ranged from a two hour increase with artemether to a 15 hour decrease.  ^j^Downgraded by 1 for serious risk of bias: four of the seven trials were at unclear risk of selection bias. When these four trials are excluded the result becomes non‐significant.  ^k^Downgraded by 1 for serious inconsistency: the mean difference in fever clearance time ranged from a 25‐hour increase with artemether to an 18‐hour decrease.  ^l^No serious imprecision: the overall meta‐analysis is powered to detect this effect. The result is statistically significant but may not be clinically important.

###### 'Summary of findings\' table 2

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------- ----------------------------------------- ---------------------------------------- -------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Artemether compared with quinine for treating adults with severe malaria**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  **Patient or population:** adults with severe malaria  **Settings:** malaria‐endemic countries  **Intervention:** intramuscular artemether  **Comparison:** intravenous or intramuscular quinine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **Illustrative comparative risks\* (95% CI)**   **Relative effect  (95% CI)**   **Number of participants  (trials)**      **Certainty of the evidence  (GRADE)**   **Comments**                           

  **Risk with quinine**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **Risk with artemether**                                                                                                                                                                                  

  Death                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **208 per 1000**                                **123 per 1000**  (87 to 173)   **RR 0.59**   (0.42 to 0.83)              716  (4 trials)                          ⊕⊕⊕⊝  MODERATE^a,b,c,d^\               Artemether probably reduces the risk of death compared to quinine.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Due to imprecision                     

  Coma resolution time                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ‐                                               ‐                               Not pooled. Little difference.            657  (2 trials)                          ⊕⊕⊝⊝  LOW^a,e,f,g^\                    Artemether may make little or no difference to coma resolution time compared to quinine.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Due to inconsistency and imprecision   

  Neurological sequelae at discharge                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         **4 per 1000**                                  **12 per 1000**\                **RR 2.92**   (0.31 to 27.86)             560  (1 trial)                           ⊕⊕⊝⊝  LOW^g,h^\                        Artemether may increase the risk of neurological sequelae compared to quinine.  However, the effects vary and it is possible artemether decreases neurological sequelae.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             (1 to 111)                                                                                                         Due to imprecision                     

  Parasite clearance time                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ‐                                               ‐                               Not pooled. Little difference apparent.   716  (4 trials)                          ⊕⊕⊕⊝  MODERATE^a,c,f,i^\               Artemether probably makes no difference to parasite clearance time compared to quinine.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Due to imprecision                     

  Fever clearance time                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ‐                                               ‐                               Not pooled. Little difference apparent.   716  (4 trials)                          ⊕⊕⊝⊝  LOW^a,c,f,j^\                    Artemether may make little or no difference to parasite clearance time compared to quinine.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Due to inconsistency and imprecision   

  \*The **assumed risk** is the median control group risk across studies. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  Abbreviations: **CI:** confidence interval; **RR:** risk ratio.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **GRADE Working Group grades of evidence**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect  **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different  **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect  **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect                                                                                                                                                                                                             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------- ----------------------------------------- ---------------------------------------- -------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^No serious risk of bias: trials are generally well conducted and at low risk of bias.  ^b^No serious inconsistency: statistically significant differences were only seen in one of the four trials. However, statistical heterogeneity between trials was low and the overall meta‐analysis is statistically significant.  ^c^No serious indirectness: all four trials compared intramuscular artemether with intravenous quinine in adults; two trials from Thailand, one each from Vietnam and Papua New Guinea  ^d^Downgraded by 1 for serious imprecision: these trials, and the overall meta‐analysis are very underpowered to detect a difference in mortality or to prove equivalence.  ^e^[Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"} and [Karbwang 1995](#CD010678-bbs2-0007){ref-type="ref-list"} reported median coma time for artemether versus quinine ([Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"}: 66 versus 48, P = 0.003; [Karbwang 1995](#CD010678-bbs2-0007){ref-type="ref-list"}: 48 versus 48). Downgraded by 1 for inconsistency: one trial found a shorter median coma resolution time with quinine, and one trial found no difference.  ^f^Downgraded by 1 for imprecision: the data could not be pooled.  ^g^No serious risk of bias: this single trial was at low risk of bias.  ^h^Downgraded by 2 for very serious imprecision: neurological sequelae in adults were uncommon. This trial is underpowered to detect or exclude clinically important differences.  ^i^Two trials found no significant difference between parasite clearance time for artemether versus quinine ([Karbwang 1992](#CD010678-bbs2-0006){ref-type="ref-list"}: mean 63.6 versus 61.6, P = 0.85; and [Seaton 1998](#CD010678-bbs2-0015){ref-type="ref-list"}: median 48 versus 52, P = 0.381). Two other trials reported significantly shorter median parasite clearance times for artemether versus quinine ([Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"}: 72 versus 90, P \< 0.001 and [Karbwang 1995](#CD010678-bbs2-0007){ref-type="ref-list"}: 54 versus 78, P = 0.007). No serious inconsistency: The two largest trials both found shorter median clearance times with artemether.  ^j^Three trials reported median fever clearance time for artemether versus quinine (127 versus 90, P \< 0.001; 32 versus 48, P =  0.034 and 79 versus 84, no significant difference) ([Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"}, [Seaton 1998](#CD010678-bbs2-0015){ref-type="ref-list"} and [Karbwang 1995](#CD010678-bbs2-0007){ref-type="ref-list"}). [Karbwang 1992](#CD010678-bbs2-0006){ref-type="ref-list"} reported mean fever clearance time and found a statistically significant reduction of about 30 hours with artemether. Downgraded by 1 for inconsistency: One trial found a shorter median fever clearance time with quinine, and two trials found a shorter time with artemether.

###### 'Summary of findings\' table 3

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------- --------------------------------------- ---------------------------------------- -------------------------- ------------------------------------------------------------------------------------------------------
  **Artemether compared with artesunate for treating adults with severe malaria**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  **Patient or population:** adults with severe malaria  **Settings:** malaria‐endemic countries  **Intervention:** intramuscular artemether  **Comparison:** intravenous or intramuscular artesunate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **Illustrative comparative risks\* (95% CI)**   **Relative effect  (95% CI)**   **Number of participants  (trials)**    **Certainty of the evidence  (GRADE)**   **Comments**               

  **Risk with artesunate**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   **Risk with artemether**                                                                                                                                                                    

  Death                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **87 per 1000**                                 **156 per 1000**  (95 to 258)   **RR 1.80**   (1.09 to 2.97)            494  (2 trials)                          ⊕⊕⊕⊝  MODERATE^a,b,c,d^\   Artemether probably increases the risk of death compared to artesunate.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Due to imprecision         

  Coma resolution time                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ‐                                               ‐                               Not pooled. No significant difference   494  (2 trials)                          ⊕⊕⊕⊝  MODERATE^a,c,e,f^\   Artemether probably makes little or no difference to coma resolution time compared to artesunate.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Due to imprecision         

  Neurological sequelae at discharge                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ‐                                               ‐                               ‐                                       0  (0 trials)                            ‐                          None of the studies looked at neurological sequelae in adults.

  Parasite clearance time                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ‐                                               ‐                               Not pooled. No significant difference   494  (2 trials)                          ⊕⊕⊕⊝  MODERATE^a,c,f,g^\   Artemether probably makes little or no difference to parasite clearance time compared to artesunate.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Due to imprecision         

  Fever clearance time                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ‐                                               ‐                               Not pooled. No significant difference   494  (2 trials)                          ⊕⊕⊕⊝  MODERATE^a,c,f,h^\   Artemether probably makes little or no difference to fever clearance time compared to artesunate.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Due to imprecision         

  \*The **assumed risk** is the median control group risk across studies. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  Abbreviations: **CI:** confidence interval; **RR:** risk ratio.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  **GRADE Working Group grades of evidence**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect  **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different  **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect  **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect                                                                                                                                                                                               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------- --------------------------------------- ---------------------------------------- -------------------------- ------------------------------------------------------------------------------------------------------

^a^No serious risk of bias: trials were generally well conducted and at low risk of bias.  ^b^No serious inconsistency: there is no statistical heterogeneity.  ^c^No serious indirectness: the two trials were conducted in Vietnam and Thailand and both compared intramuscular artemether with intravenous artesunate in adults.  ^d^Downgraded by 1 for serious imprecision: these trials, and the overall meta‐analysis are very underpowered to detect a difference in mortality or to prove equivalence.  ^e^[Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"} and [Vinh 1997](#CD010678-bbs2-0018){ref-type="ref-list"} reported median coma resolution time for artemether versus artesunate ([Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"}: 72 versus 60, P = 0.11; [Vinh 1997](#CD010678-bbs2-0018){ref-type="ref-list"}: 47 (artemether) versus 30 (artesunate IM) versus 24 (artesunate IV). No serious inconsistency: Both trials suggest an advantage with artesunate although not statistically significant.  ^f^Downgraded by 1 for serious imprecision: we could not pool these data as median data were presented for both trials.  ^g^[Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"} and [Vinh 1997](#CD010678-bbs2-0018){ref-type="ref-list"} reported median parasite clearance time ([Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"}: 72 versus 72, P = 0.97; [Vinh 1997](#CD010678-bbs2-0018){ref-type="ref-list"}: 30 (artemether) versus 24 (artesunate IM) versus 24 (artesunate IV). No serious inconsistency: Both trials found no difference between treatments.  ^h^[Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"} and [Vinh 1997](#CD010678-bbs2-0018){ref-type="ref-list"} reported median fever clearance time ([Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"}: 108 versus 108, P = 0.27; [Vinh 1997](#CD010678-bbs2-0018){ref-type="ref-list"}: 48 (artemether) versus 36 (artesunate IM) versus 30 (artesunate IV). No serious inconsistency: Both trials found no statistically significant difference between artemether and artesunate.

Background {#CD010678-sec-0024}
==========

Description of the condition {#CD010678-sec-0025}
----------------------------

Malaria is a febrile illness caused by *Plasmodium* parasites, which are transmitted to humans through the bite of infected female anopheline mosquitoes. Five species of *Plasmodium* cause this disease in humans, of which *Plasmodium falciparum* is the most common worldwide, and is responsible for almost all of the severe disease and deaths ([WHO 2000](#CD010678-bbs2-0067){ref-type="ref-list"}; [WHO 2008](#CD010678-bbs2-0068){ref-type="ref-list"}).

Severe malaria is diagnosed on the basis of a positive blood slide or antigen test for malaria, plus the presence of clinical or laboratory features of vital organ dysfunction. These include impaired consciousness, coma, convulsions, respiratory distress, shock (systolic blood pressure \< 70 mmHg in adults, \< 50 mmHg in children), jaundice, haemoglobinuria, hypoglycaemia, severe metabolic acidosis, and anaemia ([WHO 2010](#CD010678-bbs2-0069){ref-type="ref-list"}). Cerebral malaria is one form of severe malaria, where the patient has some impairment of consciousness and cognition. This can vary from slight disorientation through to deep coma where the patient is unconscious and unrousable. Even with correct treatment cerebral malaria can cause a mortality rate of up to 20%, and a small proportion of people that survive infection can have persistent neurological sequelae ([Jaffar 1997](#CD010678-bbs2-0050){ref-type="ref-list"}).

People living in malaria‐endemic regions can develop a naturally acquired immunity to malaria through repeated exposure to the parasite over five to 10 years ([Doolan 2009](#CD010678-bbs2-0044){ref-type="ref-list"}). This partial immunity is protective against the most severe forms of the disease, and as a consequence, in high transmission settings mortality from severe malaria is highest in young children and decreases with increasing age ([WHO 2010](#CD010678-bbs2-0069){ref-type="ref-list"}).

Parenteral quinine used to be the standard treatment for severe malaria despite sporadic observations of resistance. Clinical and in vitro resistance to quinine has been observed in Southeast Asia, but not consistently in Africa ([Wongsrichanalai 2002](#CD010678-bbs2-0071){ref-type="ref-list"}; [Cui 2015](#CD010678-bbs2-0041){ref-type="ref-list"}). Artemisinin derivatives have become the keystone of malaria treatment and control ([WHO 2015](#CD010678-bbs2-0070){ref-type="ref-list"}). They are effective at killing all asexual blood stages of *P falciparum* parasites, as well as disrupting sexual development, resulting in rapid clinical and parasitological cure and a reduction in malaria transmission rates ([Tyagi 2018](#CD010678-bbs2-0066){ref-type="ref-list"}).

Evidence of resistance to artemisinin combination therapy has been reported for about a decade, initially in the Thai‐Cambodia border region and now increasingly in Southeast Asia. Resistance has been characterized by delayed parasite clearance time in patients with uncomplicated and severe malaria ([Ashley 2014](#CD010678-bbs2-0039){ref-type="ref-list"}; [Hawkes 2014](#CD010678-bbs2-0046){ref-type="ref-list"}; [Menard 2016](#CD010678-bbs2-0055){ref-type="ref-list"})

The World Health Organization (WHO) strongly recommends parenteral artesunate as the drug of choice and artemether in preference to quinine for the treatment of severe malaria in adults and children, followed by a complete course of an effective artemisinin‐based combination therapy (ACT) as soon as the patient can take oral medications ([WHO 2015](#CD010678-bbs2-0070){ref-type="ref-list"}). The WHO based their recommendation of parenteral artesunate on evidence from two large multi‐centre clinical trials that demonstrated the superiority of intravenous artesunate over the standard treatment, quinine ([Dondorp 2005](#CD010678-bbs2-0042){ref-type="ref-list"}; [Dondorp 2010](#CD010678-bbs2-0043){ref-type="ref-list"}). A Cochrane Review of available data concluded that treating people that have severe malaria with artesunate instead of quinine would reduce the risk of death by 39% in adults and 24% in children ([Sinclair 2012](#CD010678-bbs2-0063){ref-type="ref-list"}).

Description of the intervention {#CD010678-sec-0026}
-------------------------------

Artesunate is only one of a number of antimalarials derived from artemisinin, which is extracted from the herb *Artemesia annua* and is the active ingredient in a Chinese herbal remedy for fever. Once ingested or injected, artemisinin derivatives undergo conversion to dihydroartemisinin, the active metabolite, which has a broad spectrum of activity against the blood stage asexual *Plasmodium* parasites ([ter Kuile 1993](#CD010678-bbs2-0065){ref-type="ref-list"}; [Navaratnam 2000](#CD010678-bbs2-0058){ref-type="ref-list"}). Artemisinin derivatives clear parasites from the peripheral blood quicker than other antimalarials, but only artesunate has been shown to impact mortality.

Unlike artesunate, artemether is poorly soluble in water and the parenteral formulation is only available as a pre‐mixed oil‐based solution for intramuscular injection (80 mg/mL for use in adults and 40 mg/mL for children). The standard dose is 3.2 mg/kg on admission followed by 1.6 mg/kg once daily until oral therapy is tolerated ([WHO 2010](#CD010678-bbs2-0069){ref-type="ref-list"}). Peak plasma concentrations typically occur around six hours after intramuscular injection, but in severely ill children with poor peripheral perfusion, absorption can be highly erratic ([Karbwang 1997](#CD010678-bbs2-0051){ref-type="ref-list"}; [Murphy 1997](#CD010678-bbs2-0057){ref-type="ref-list"}; [Mithwani 2004](#CD010678-bbs2-0056){ref-type="ref-list"}).

Conversely, artesunate is supplied as a dry powder for mixing with sodium bicarbonate prior to either intravenous or intramuscular injection ([WHO 2010](#CD010678-bbs2-0069){ref-type="ref-list"}). The absorption of artesunate is more reliable compared with artemether, with peak plasma concentrations following intramuscular injection occurring at around one hour ([Illet 2002](#CD010678-bbs2-0049){ref-type="ref-list"}; [Nealon 2002](#CD010678-bbs2-0059){ref-type="ref-list"}; [Hien 2004](#CD010678-bbs2-0047){ref-type="ref-list"}). These more favourable pharmacokinetic properties of artesunate moved research attention away from artemether; and artesunate now has a stronger evidence base and is the preferred therapy ([WHO 2010](#CD010678-bbs2-0069){ref-type="ref-list"}; [Sinclair 2012](#CD010678-bbs2-0063){ref-type="ref-list"}).

How the intervention might work {#CD010678-sec-0027}
-------------------------------

Deaths from severe malaria often occur between one and two days following hospital admission. Consequently, to be effective, antimalarial drugs need to achieve rapid therapeutic blood concentrations following administration. Artemisinins, especially artesunate and artemether, result in more rapid parasite clearance (being active on gametocytes (immature forms) and are safer and simpler to administer ([ter Kuile 1993](#CD010678-bbs2-0065){ref-type="ref-list"}; [Adjuik 2004](#CD010678-bbs2-0037){ref-type="ref-list"}). Artemether is a potent and rapidly acting blood schizonticide which is highly efficacious in treating complicated *P falciparum* malaria including cerebral malaria. The drug is given by intramuscular injection in the gluteal muscle. Its quick onset of action and high efficacy in bringing down the parasite load are the properties which make this drug a suitable therapeutic option against *P falciparum* infection. Artemether may be an excellent alternative for treatment of severe malaria and cerebral malaria in rural areas where facilities for intravenous administration may not yet be optimal and might increase the risk of infection.

Why it is important to do this review {#CD010678-sec-0028}
-------------------------------------

A number of African countries incorporated intramuscular artemether into their national guidelines prior to the WHO recommendation for artesunate. Systematic reviews concluded that intramuscular artemisinin derivatives (including both artesunate and artemether) were not inferior to quinine in preventing deaths from malaria, but were safer and easier to administer ([McIntosh 2000](#CD010678-bbs2-0054){ref-type="ref-list"}; [AQMSG 2001](#CD010678-bbs2-0038){ref-type="ref-list"}; [Kyu 2009](#CD010678-bbs2-0052){ref-type="ref-list"}).

Following the WHO recommendation for artesunate as the preferred treatment for severe malaria, there is a need to re‐evaluate the role of intramuscular artemether in the management of severe malaria in adults and children.

Objectives {#CD010678-sec-0029}
==========

To assess the efficacy and safety of intramuscular artemether versus any other parenteral medication in the treatment of severe malaria in adults and children.

Methods {#CD010678-sec-0030}
=======

Criteria for considering studies for this review {#CD010678-sec-0031}
------------------------------------------------

### Types of studies {#CD010678-sec-0032}

Randomized controlled trials (RCTs).

### Types of participants {#CD010678-sec-0033}

Adults and children (\< 15 years of age) with severe malaria.

### Types of interventions {#CD010678-sec-0034}

#### Intervention {#CD010678-sec-0035}

Intramuscular artemether

#### Control {#CD010678-sec-0036}

Any other parenteral medication for the treatment of severe malaria

### Types of outcome measures {#CD010678-sec-0037}

#### Primary outcomes {#CD010678-sec-0038}

Death from any cause

#### Secondary outcomes {#CD010678-sec-0039}

Coma resolution timeNeurological sequelae (such as blindness, deafness, hemiplegia and others)Time to hospital dischargeParasite clearance timeFever clearance timeNeed for blood transfusionSevere anaemiaAdverse events (including hypoglycaemia, tinnitus, nausea, vomiting, haematological and cardiac‐related adverse events)

Search methods for identification of studies {#CD010678-sec-0040}
--------------------------------------------

We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press and in progress).

### Electronic searches {#CD010678-sec-0041}

#### Databases {#CD010678-sec-0042}

We examined the following databases up to 7 September 2018 using the search terms detailed in [Appendix 1](#CD010678-sec-0117){ref-type="app"}:  Cochrane Infectious Diseases Group Specialized Register; Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library; MEDLINE (PubMed); Embase, LILACS and ISI Web of Science. We also searched the WHO clinical trial registry platform, ClinicalTrials.gov and the metaRegister of Controlled Trials (mRCT) up to 7 September 2018 for ongoing trials using 'artemether\', 'severe malaria\', 'complicated malaria\', 'artesunate\', 'arteether\', and 'child\*\' as search terms.

### Searching other resources {#CD010678-sec-0043}

#### Conference proceedings {#CD010678-sec-0044}

We searched relevant proceedings of the following meetings for trial information: Multilateral Initiative on Malaria (MIM) Pan‐African Malaria Conference; European Congress on Tropical Medicine and International Health; and American Society of Tropical Medicine and Hygiene (7 September 2018).

#### Researchers {#CD010678-sec-0045}

We contacted researchers working in the field and the WHO for unpublished and ongoing trials.

#### Reference lists {#CD010678-sec-0046}

We checked the reference lists of existing reviews and of all trials identified by the above methods.

Data collection and analysis {#CD010678-sec-0047}
----------------------------

### Selection of studies {#CD010678-sec-0048}

Two review authors screened the abstract of each title obtained from the search for potentially relevant studies. We retrieved the corresponding full articles of these identified studies, and two review authors assessed inclusion by using an eligibility form. We independently screened each search result, assessed each article, and resolved any discrepancies between eligibility results through discussion. Also, we listed the excluded studies and the reasons for their exclusion.

### Data extraction and management {#CD010678-sec-0049}

Two review authors independently extracted data from each study report onto a pre‐designed data extraction form. We discussed any discrepancies with a third review author. We contacted the corresponding publication author in the case of unclear information or missing data. For each outcome we aimed to extract the number of participants randomized and the number analysed in each treatment group. For dichotomous outcomes, we recorded the number of participants experiencing the event and the number assessed in each treatment group. For continuous outcomes, we extracted arithmetic means and standard deviations for each treatment group, together with the numbers assessed in each group.

Where baseline proportions of participants in the intervention and control arms in whom antipyretics were administered varied, we only included trials that reported fever clearance time and provided additional information about antipyretics use at baseline for participants in both intervention and control arm to avoid confounding in the summary estimate for fever clearance. Where there was significant difference between antipyretic use at baseline in intervention and control arms, we only reported fever clearance time in a table. We defined cure rates in this review as time from first dose to first negative parasite reading for two consecutive readings.

### Assessment of risk of bias in included studies {#CD010678-sec-0050}

Two review authors independently assessed the risk of bias of each included study using Cochrane\'s 'Risk of bias\' tool ([Higgins 2011](#CD010678-bbs2-0048){ref-type="ref-list"}). We followed the guidance for making judgements on the risk of bias in six domains: sequence generation; allocation concealment; blinding (of participants, personnel and outcome assessors); incomplete outcome data; selective outcome reporting; and other risk of bias (such as the trial stopped early). We categorized these judgements as low risk of bias, high risk of bias, or unclear risk of bias.

### Measures of treatment effect {#CD010678-sec-0051}

We calculated results using risk ratios for dichotomous data, and mean difference values for continuous data, and have presented these effect estimates with 95% confidence intervals (CIs). We treated time‐to‐event outcomes as continuous data and accordingly mean difference calculated from mean time in intervention versus control groups. Where the data were not normally distributed and medians were reported, we excluded them from the meta‐analysis and reported them in additional tables.

### Unit of analysis issues {#CD010678-sec-0052}

For multiple arm trials, we combined all relevant experimental intervention groups of the trial into a single group, and also combined all relevant control intervention groups into a single control group. For dichotomous outcomes, both the sample sizes and the numbers of people with events were added across groups. For continuous outcomes, we combined means and standard deviations using methods described in the *Cochrane Handbook for Systematic Reviews of Interventions*.

### Dealing with missing data {#CD010678-sec-0053}

We analysed data according to the intention‐to‐treat principle (all randomized participants should be analysed in the groups to which they were originally assigned). If there were discrepancies between the number randomized and the number analysed, we calculated the percentage loss to follow‐up for each treatment group and reported this information.

However, if for some trials it was unclear whether there was loss to follow‐up, we entered the number analysed into [Review Manager 2014](#CD010678-bbs2-0062){ref-type="ref-list"} whenever these figures were available. By attempting to carry out a complete case analysis, we avoided making assumptions about the outcomes of participants lost to follow‐up. Where possible, we contacted authors for missing data.

### Assessment of heterogeneity {#CD010678-sec-0054}

We looked for statistical heterogeneity by inspecting the forest plots for overlapping CIs, applying the Chi^2^ test (P \< 0.10 considered statistically significant) and the I^2^ statistic (I^2^ value \< 50% used to denote moderate levels of heterogeneity).

### Assessment of reporting biases {#CD010678-sec-0055}

Since asymmetry of funnel plots may result from publication bias, heterogeneity, or poor methodological quality ([Sterne 2011](#CD010678-bbs2-0064){ref-type="ref-list"}), we planned to examine funnel plots using Review Manager 5 (RevMan 5) but found an insufficient number of trials to do this ([Review Manager 2014](#CD010678-bbs2-0062){ref-type="ref-list"}).

### Data synthesis {#CD010678-sec-0056}

We analysed the data using RevMan 5 ([Review Manager 2014](#CD010678-bbs2-0062){ref-type="ref-list"}). In the first instance, we applied a fixed‐effect meta‐analysis. However, if we detected moderate heterogeneity but still considered it appropriate to combine the trials, we then used a random‐effects approach. Where heterogeneity was very high such that meta‐analysis was not appropriate, we displayed the results in forest plots or tables but did not combine the results. Where data were only presented as medians and ranges, we have presented the results in tables.

For both dichotomous and continuous outcomes, optimal information size was calculated. The optimal information size (OIS) can be defined as the minimum amount of information needed in a meta‐analysis to obtain reliable conclusions about an intervention. The optimal information size calculations were performed using a power calculator available at [www.sealedenvelope.com/power](www.sealedenvelope.com/power). All calculations were performed for a power of 80% and an α error of 0.05 and the proportion in the control groups were taken from the median control group risk across trials. Also, a maximum 3% risk difference was chosen to represent equivalence ([Table 4](#CD010678-tbl-0004){ref-type="table"}). For the continuous outcomes (coma resolution time, parasite clearance time, and fever clearance time) a six‐hour time difference was chosen to represent a clinically important benefit ([Table 5](#CD010678-tbl-0005){ref-type="table"}).

###### Optimal information size calculations; dichotomous outcomes

  ----------------------- ------------------ ------------------------------------ -------------------------------------- ------------------ ----------------------------
  **Outcome**             **Type of test**   **Proportion in control group^a^**   **Proportion in Intervention group**   **Estimated RR**   **Total sample size^b,c^**
  Death                   Superiority        0.15                                 0.12                                   0.80               4068
  Equivalence             0.15               0.12 to 0.18^d^                      ‐                                      5956               
  Neurological sequelae   Superiority        0.25                                 0.20                                   0.80               2184
  Equivalence             0.25               0.22 to 0.28^d^                      ‐                                      8760               
  ----------------------- ------------------ ------------------------------------ -------------------------------------- ------------------ ----------------------------

^a^The proportion in the control group is taken from the median control group risk across trials.  ^b^These calculation were performed using a power calculator available at [www.sealedenvelope.com/power](www.sealedenvelope.com/power)  ^c^All calculations were performed for a power of 80% and an α error of 0.05.  ^d^A maximum 3% risk difference was chosen to represent equivalence.

###### Optimal information size calculations; continuous outcomes

  ------------------------- ------------------ ------------------------------ ----------------------------------- ------------------- ----------------------------
  **Outcome**               **Type of test**   **Mean in control group^a^**   **Mean in Intervention group^b^**   **SD of outcome**   **Total sample size^c,d^**
  Coma resolution time      Superiority        25                             19                                  20                  350
  Equivalence               25                 19 to 31                       20                                  382                 
  Parasite clearance time   Superiority        42                             36                                  20                  350
  Equivalence               42                 36 to 48                       20                                  382                 
  Fever clearance time      Superiority        48                             42                                  20                  350
  Equivalence               48                 36 to 54                       20                                  382                 
  ------------------------- ------------------ ------------------------------ ----------------------------------- ------------------- ----------------------------

^a^The mean in the control group is taken from the median control group across studies.  ^b^A six‐hour time difference was chosen to represent a clinically important benefit.  ^c^These calculations were performed using a power calculator available at: [www.sealedenvelope.com/power](www.sealedenvelope.com/power)  ^d^All calculation were performed for a power of 80% and an α error of 0.05.

#### Certainty of the evidence {#CD010678-sec-0057}

We assessed the certainty of the evidence following the GRADE approach and defined 'certainty\' as an assessment of our confidence in the estimates of effect ([Guyatt 2008](#CD010678-bbs2-0045){ref-type="ref-list"}). We rated each outcome as follows.

High: we are very confident that the true effect lies close to that of the estimate of the effect.Moderate: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect.Low: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.Very low: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

As all the included studies were RCTs the evidence for each outcome started as high certainty, but we would downgrade if there were valid reasons to do so within the following five categories: risk of bias; imprecision; inconsistency; indirectness; and publication bias ([Balshem 2011](#CD010678-bbs2-0040){ref-type="ref-list"}). We summarized the certainty of the evidence for each outcome in a 'Summary of findings' table.

### Subgroup analysis and investigation of heterogeneity {#CD010678-sec-0058}

We grouped the analysis and results by children and adults. We reported results by whether the studies were carried out in Africa or in Asia. We examined whether loading dose or quinine influenced outcomes.

### Sensitivity analysis {#CD010678-sec-0059}

We conducted a sensitivity analysis to investigate the robustness of the results to the risk of bias components by including only trials that concealed the allocation and had low incomplete outcome data (\< 10%).

Results {#CD010678-sec-0060}
=======

Description of studies {#CD010678-sec-0061}
----------------------

See the [Characteristics of included studies](#CD010678-sec-0126){ref-type="sec"} section for details of the included trials.

### Results of the search {#CD010678-sec-0062}

We conducted the literature search up to 7 September 2018 and identified 87 references (see [Figure 1](#CD010678-fig-0001){ref-type="fig"}).

![PRISMA diagram.](nCD010678-AFig-FIG01){#CD010678-fig-0001}

In the previous version of this Cochrane Review, we identified 77 titles and abstracts from the electronic search of databases and 2 additional articles after contacting researchers and screening reference lists ([Esu 2014](#CD010678-bbs2-0073){ref-type="ref-list"}). After we removed duplicates, 77 records remained. Of these, we obtained 35 potentially eligible articles. We identified 18 studies that fulfilled the selection criteria and reported on outcomes of interest.

For this review update, we identified 10 additional titles and abstracts from electronic searches of databases. There were 87 articles after we removed duplicates. Of these, there was only one potentially eligible article. This new study met the inclusion criteria ([Bobossi‐Serengbe 2015](#CD010678-bbs2-0003){ref-type="ref-list"}).

### Included studies {#CD010678-sec-0063}

In the previous version of this review, we included 18 RCTs, enrolling 2662 participants. Twelve trials enrolled children only (1447 participants aged between six months and 15 years), and six trials enrolled older children and adults (1215 participants aged between 13 and 79 years).

In this review update, we included one additional RCT enrolling 212 participants (children aged between six and 59 months) ([Bobossi‐Serengbe 2015](#CD010678-bbs2-0003){ref-type="ref-list"}).

#### Location {#CD010678-sec-0064}

The trials in children were primarily conducted in Africa: Nigeria (five trials), Sudan (two trials), Central African Republic (one trial), the Gambia (one trial), Kenya (one trial), Malawi (one trial), and Mali (one trial); with only one trial from Asia (India).

Five adult trials were conducted in Asia: Vietnam (three trials), and Thailand (two trials); and one in Oceania; Papua New Guinea (one trial). We have attached a three‐letter country code to each trial ID to aid forest plot interpretation.

#### Interventions {#CD010678-sec-0065}

All 13 trials in children compared artemether with quinine. In most trials, artemether was given by intramuscular injection, with a loading dose of 3.2 mg/kg body weight followed by maintenance doses of 1.6 mg/kg for three to six days (see [Table 6](#CD010678-tbl-0006){ref-type="table"} for details). Only three trials followed this with oral therapy once tolerated ([Murphy 1996](#CD010678-bbs2-0009){ref-type="ref-list"}; [van Hensbroek 1996](#CD010678-bbs2-0017){ref-type="ref-list"}; [Taylor 1998](#CD010678-bbs2-0016){ref-type="ref-list"}). For quinine, nine trials administered the WHO recommended loading dose of 20 mg/kg of intravenous or intramuscular quinine followed by a maintenance dose of 10 mg/kg. However, [van Hensbroek 1996](#CD010678-bbs2-0017){ref-type="ref-list"} administered the maintenance dose at 12‐hourly intervals instead of eight‐hour intervals (see [Table 6](#CD010678-tbl-0006){ref-type="table"}).

###### Characteristics of trials comparing artemether and quinine in children

  ------------------------------------------------------------------- ------------------- ------------------------ ----------------------------- ------------------------------------------------ -------------------------------- -------------------------- ------------------------------------------------------- ------------
  **Trial ID**                                                        **Year of study**   **Age limits**           **Quinine dosing schedule**   **Artemether dosing schedule**                                                                                                                                       
  **Loading dose**                                                    **Maintainance**    **Follow‐on therapy**    **Loading dose**              **Maintainance**                                 **Follow‐on therapy**                                                                                               
  [Adam 2002](#CD010678-bbs2-0001){ref-type="ref-list"}               2002                'Children\'              20 mg/kg IV                   10 mg/kg IV every 8 hours for 72 hours           Oral quinine for 7 days          3.2 mg/kg IM               1.6 mg/kg IM once daily for 4 days                      None
  [Aguwa 2010](#CD010678-bbs2-0002){ref-type="ref-list"}              2007                6 months to 12 years     20 mg/kg IV or IM             10 mg/kg IV/IM every 8 hours                     None                             3.2 mg/kg IM               1.6 mg/kg IM once daily for 2 days                      None
  [Bobossi‐Serengbe 2015](#CD010678-bbs2-0003){ref-type="ref-list"}   2010                6 to 59 months           10 mg/kg IV                   10 mg/kg IV every 4 hours                        Oral quinine for 7 days          2 mg/kg IM twice daily     2 mg/kg IM once daily for 2 days                        None
  [Huda 2003](#CD010678-bbs2-0005){ref-type="ref-list"}               2001                \< 14 years              20 mg/kg IV                   10 mg/kg IV every 8 hours                        Quinine to complete 7 days       1.6 mg/kg IM twice daily   1.6 mg/kg IM once daily for 5 days                      None
  [Minta 2005](#CD010678-bbs2-0008){ref-type="ref-list"}              2004                3 months to 15 years     20 mg/kg IV                   10 mg/kg IV every 8 hours                        Quinine 10 mg/kg every 8 hours   3.2 mg/kg IM twice daily   1.6 mg/kg IM once daily for 4 days                      None
  [Murphy 1996](#CD010678-bbs2-0009){ref-type="ref-list"}             1996                5 months to 12 years     20 mg/kg IV                   10 mg/kg IV every 8 hours                        SP once                          3.2 mg/kg IM               1.6 mg/kg IM once daily for 4 days                      SP once
  [Ojuawo 1998](#CD010678-bbs2-0010){ref-type="ref-list"}             1998                Mean age about 4 years   10 mg/kg IV                   10 mg/kg IV every 8 hours                        Quinine to complete 7 days       3.2 mg/kg IM               1.6 mg/kg IM 12 hrs later, then once daily for 2 days   None
  [Olumese 1999](#CD010678-bbs2-0011){ref-type="ref-list"}            1999                11 months to 5 years     20mg/kg IV                    10mg/kg IV every 8 hours                         Quinine to complete 7 days       3.2 mg/kg IM               1.6 mg/kg IM once daily for 4 days                      None
  [Osonuga 2009](#CD010678-bbs2-0012){ref-type="ref-list"}            2009                1 to 12 years            10 mg/kg IV                   10 mg/kg IV every 8 hours                        Quinine to complete 7 days       1.6 mg/kg IM twice daily   1.6 mg/kg IM once daily for 4 days                      None
  [Satti 2002](#CD010678-bbs2-0014){ref-type="ref-list"}              1996                3 months to 15 years     10 mg/kg IV                   10 mg/kg IV every 8 hours                        Quinine to complete 7 days       1.6 mg/kg IM twice daily   1.6 mg/kg IM once daily for 4 days                      None
  [Taylor 1998](#CD010678-bbs2-0016){ref-type="ref-list"}             1994                Mean age of 3 years      20 mg/kg IV                   10 mg/kg IV every 8 hours for at least 2 doses   SP once                          3.2 mg/kg IM               1.6 mg/kg IM once daily for 2 days at least             SP once
  [van Hensbroek 1996](#CD010678-bbs2-0017){ref-type="ref-list"}      1994                1 to 9 years             20 mg/kg IV                   10 mg/kg IV every 12 hours                       Quinine to complete 5 days       3.2 mg/kg IM               1.6 mg/kg IM once daily for 3 days                      SP once^a^
  [Walker 1993](#CD010678-bbs2-0019){ref-type="ref-list"}             1993                1 to 5 years             20 mg/kg IV                   10 mg/kg IV every 8 hours                        Quinine to complete 7 days       3.2 mg/kg IM               1.6 mg/kg IM once daily for 4 days                      None
  ------------------------------------------------------------------- ------------------- ------------------------ ----------------------------- ------------------------------------------------ -------------------------------- -------------------------- ------------------------------------------------------- ------------

Abbreviations: IM = intramuscular; IV = intravenous; SP = sulphadoxine‐pyrimethamine.  ^a^Only in the second and third years of the study.

In adults, four trials compared artemether with quinine ([Karbwang 1992](#CD010678-bbs2-0006){ref-type="ref-list"}; [Karbwang 1995](#CD010678-bbs2-0007){ref-type="ref-list"}; [Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"}; [Seaton 1998](#CD010678-bbs2-0015){ref-type="ref-list"}); and two trials compared artemether with artesunate ([Vinh 1997](#CD010678-bbs2-0018){ref-type="ref-list"}; [Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"}). Artemether was given intramuscularly over three to seven days with slight variations in dosing (see [Table 7](#CD010678-tbl-0007){ref-type="table"} and [Table 8](#CD010678-tbl-0008){ref-type="table"}); and all four trials administered quinine at the WHO‐recommended loading dose.

###### Characteristics of trials comparing artemether and quinine in adults

  ----------------------------------------------------------- ------------------- ----------------------- ----------------------------- ----------------------------------- ------------------------------------------ -------------- ------------------------------------ ------------------------------------------
  **Trial ID**                                                **Year of study**   **Age limits**          **Quinine dosing schedule**   **Artemether dosing schedule**                                                                                                     
  **Loading dose**                                            **Maintainance**    **Follow‐on therapy**   **Loading dose**              **Maintainance**                    **Follow‐on therapy**                                                                          
  [Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"}       1996                15 to 79 years          20 mg/kg IM                   10 mg/kg IM every 8 hours           Quinine or mefloquine to complete 7 days   4 mg/kg IM     2 mg/kg IM once daily for 4 days     Quinine or mefloquine to complete 7 days
  [Karbwang 1992](#CD010678-bbs2-0006){ref-type="ref-list"}   1991                15 to 45 years          20 mg/kg IV                   10 mg/kg every 8 hours for 7 days   Quinine to complete 7 days                 160 mg IM      80 mg IM once daily for 6 days       None
  [Karbwang 1995](#CD010678-bbs2-0007){ref-type="ref-list"}   1994                15 to 55 years          20 mg/kg IV                   10 mg/kg every 8 hours for 7 days   Quinine to complete 7 days                 160 mg IM      80 mg IM once daily for 6 days       None
  [Seaton 1998](#CD010678-bbs2-0015){ref-type="ref-list"}     1995                \> 12 years             20 mg/kg IV                   10 mg/kg IV every 8 hours           Quinine to complete 7 days                 3.2 mg/kg IM   1.6 mg/kg IM once daily for 4 days   None
  ----------------------------------------------------------- ------------------- ----------------------- ----------------------------- ----------------------------------- ------------------------------------------ -------------- ------------------------------------ ------------------------------------------

Abbreviations: IM = intramuscular; IV = intravenous.

###### Characteristics of studies comparing artemether and artesunate in adults

  ------------------------------------------------------- ------------------- ----------------------- -------------------------------- --------------------------------- ----------------------- ----------------- -------------------------------------- ------------------------------------------
  **Trial ID**                                            **Year of study**   **Age limits**          **Artemether dosing schedule**   **Artesunate dosing schedule**                                                                                     
  **Loading dose**                                        **Maintainance**    **Follow‐on therapy**   **Loading dose**                 **Maintainance**                  **Follow‐on therapy**                                                            
  [Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"}    2003                15 to 77 years          3.2 mg/kg IM                     1.6 mg/kg IM daily                None                    2.4 mg/kg IM      1.2 mg/kg IM once daily                2 mg/kg of artesunate to complete 7 days
  [Vinh 1997](#CD010678-bbs2-0018){ref-type="ref-list"}   1994                15 to 66 years          200 mg IM                        100 mg IM once daily for 3 days   Mefloquine once         120 mg IM or IV   60 mg IM or IV once daily for 3 days   Mefloquine once
  ------------------------------------------------------- ------------------- ----------------------- -------------------------------- --------------------------------- ----------------------- ----------------- -------------------------------------- ------------------------------------------

Abbreviations: IM = intramuscular; IV = intravenous.

#### Supportive care {#CD010678-sec-0066}

Twelve trials in children reported measurement of blood glucose on admission, but only nine trials reported any subsequent active monitoring for hypoglycaemia.

Only one trial in adults reported measuring blood glucose on admission and monitored hypoglycaemia up to 24 hours after admission ([Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"}).

#### Outcome measures {#CD010678-sec-0067}

Eighteen trials reported death, a measure of coma resolution, fever clearance and parasite clearance as outcomes. Eleven trials reported neurological sequelae at discharge. Only two trials reported duration of hospital stay ([Aguwa 2010](#CD010678-bbs2-0002){ref-type="ref-list"}; [Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"}); and two trials reported on the number of children requiring blood transfusions ([Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"}; [Olumese 1999](#CD010678-bbs2-0011){ref-type="ref-list"}). Twelve trials reported on adverse events including episodes of hypoglycaemia ([Karbwang 1992](#CD010678-bbs2-0006){ref-type="ref-list"}; [Walker 1993](#CD010678-bbs2-0019){ref-type="ref-list"}; [Karbwang 1995](#CD010678-bbs2-0007){ref-type="ref-list"}; [Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"}; [Murphy 1996](#CD010678-bbs2-0009){ref-type="ref-list"}; [van Hensbroek 1996](#CD010678-bbs2-0017){ref-type="ref-list"}; [Seaton 1998](#CD010678-bbs2-0015){ref-type="ref-list"}; [Adam 2002](#CD010678-bbs2-0001){ref-type="ref-list"}; [Huda 2003](#CD010678-bbs2-0005){ref-type="ref-list"}; [Minta 2005](#CD010678-bbs2-0008){ref-type="ref-list"}; [Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"}; [Bobossi‐Serengbe 2015](#CD010678-bbs2-0003){ref-type="ref-list"}). We have listed the outcome definitions used in the included trials in [Table 9](#CD010678-tbl-0009){ref-type="table"}.

###### Definitions of outcome measures used in the review

  ------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  **Trial ID**                                                        **Coma resolution time**                                                                                                                **Fever clearance time**                                                                                                                                               **Parasite clearance time**                                                                                                                                                                                                   **Hypoglycaemia**
  [Adam 2002](#CD010678-bbs2-0001){ref-type="ref-list"}               Mean value (h) reported and defined as a Blantyre coma score of 5 recorded for at least 24 hours                                        Mean value (h) reported and defined as the time after which the temperature remained normal (axillary temperature \< 37.5 °C)                                          Mean value (h) reported and defined as the time passed from admission and start of treatment until 2 consecutive negative smears. Blood films repeated every 8 hours.                                                         Number of episodes (n/N) reported but not defined
  [Aguwa 2010](#CD010678-bbs2-0002){ref-type="ref-list"}              Proportions with coma resolution on D3 reported but not defined                                                                         Proportions with fever clearance on D3 and D14 reported and defined as body temperature ≤ 37.5 °C after commencement of treatment                                      Proportions with parasite clearance on D3 and D14. Parasite clearance was taken as adequate clinical and parasitological response (ACPR) at days 3 and 14. Parasite count taken on D0, D3 and D14.                            Not reported
  [Bobossi‐Serengbe 2015](#CD010678-bbs2-0003){ref-type="ref-list"}   Not reported                                                                                                                            Not reported                                                                                                                                                           Proportions with parasite clearance on D3 and D7 reported but not defined.                                                                                                                                                    Not reported
  [Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"}               Median value (h) reported and defined as the time to reach a score of 15 on the Glasgow Coma Scale                                      Median value (h) reported but not defined.                                                                                                                             Median value (h) reported and defined as the time passed from admission and start of treatment until 3 consecutive negative blood smears. Blood films repeated every 4 hours for the first 24 hours and then every 6 hours.   Number of episodes (n/N) reported but not defined
  [Huda 2003](#CD010678-bbs2-0005){ref-type="ref-list"}               Glasgow coma scale was used in grading the level of consciousness of the patients every 8 hours                                         Mean value (h) reported and defined as time to clearance of fever                                                                                                      Mean value (h) reported but not defined                                                                                                                                                                                       Not reported
  [Karbwang 1992](#CD010678-bbs2-0006){ref-type="ref-list"}           Unclear if values reported are means or medians (h)                                                                                     Mean value (h) reported and defined as time for the temperature to fall below 37.5 °C and remain that value for 72 hours                                               Mean value (h) reported and defined as the time for the parasite count to fall below the level of microscopic detection (thick film)                                                                                          Not reported
  [Karbwang 1995](#CD010678-bbs2-0007){ref-type="ref-list"}           Median value (h) reported and defined as the time taken for the patients to recover completely from unconciousness                      Mean value (h) reported and defined as time for the temperature to fall below 37.5 °C and remain that value for 72 hours                                               Median value (h) reported and defined as the time taken for parasite count to fall below the level of microscopic detection (thick film)                                                                                      Not reported
  [Minta 2005](#CD010678-bbs2-0008){ref-type="ref-list"}              Mean value (h) reported and defined as the time to normalization of consciousness                                                       Mean value (h) reported but not defined                                                                                                                                Mean value (h) reported and defined as time till negative parasitaemia result                                                                                                                                                 Not reported
  [Murphy 1996](#CD010678-bbs2-0009){ref-type="ref-list"}             Median value (h) reported but not described                                                                                             Median value (h) reported but not described                                                                                                                            Median value (h) reported but not described. Every 4 hours until clearance                                                                                                                                                    Not reported
  [Ojuawo 1998](#CD010678-bbs2-0010){ref-type="ref-list"}             Mean value (h) reported and defined as the interval between onset of therapy and the attainment of full consciousness                   Mean value (h) reported and defined as the interval between the onset of therapy and the time the body temperature is ≤ 37 °C and remained so                          Defined as: 2 successive thick blood films done at 12 hours interval are negative for asexual forms of *Plasmodium* species                                                                                                   Not reported
  [Olumese 1999](#CD010678-bbs2-0011){ref-type="ref-list"}            Mean value (h) reported and defined as time to regain full consciousness                                                                Mean value (h) reported and defined as the time for temperature to fall below 37.5 °C and remain so for at least 48 hours                                              Mean value (h) reported and defined as the time from start of drug administration to the first of 2 consecutive negative thick smears remaining negative until day 7                                                          Not reported
  [Osonuga 2009](#CD010678-bbs2-0012){ref-type="ref-list"}            Mean value (h) reported and defined as time to attainment of a Blantyre score of 5 for at least 24 hours from initiation of treatment   Mean value (h) reported but not defined                                                                                                                                Mean value (h) reported but not defined. Thick and thin film done on D0 and repeated on Days 3, 7 and 14                                                                                                                      Not reported
  [Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"}                Median value (h) reported and defined as time to Glasgow Coma Score of 15.                                                              Median value (h) reported and defined as the time for temperature to fall below 37.5 °C and remain so                                                                  Median value (h) reported and defined as the time to clear all parasites                                                                                                                                                      Number of episodes (n/N) reported but not defined
  [Satti 2002](#CD010678-bbs2-0014){ref-type="ref-list"}              Mean value (h) reported and defined as time to regaining consciousness                                                                  Mean value (h) reported and defined as the time for temperature to fall below 37.5 °C                                                                                  Mean value (h) reported and defined as time to clear parasites measured every 6 hours till clearance                                                                                                                          Not reported
  [Seaton 1998](#CD010678-bbs2-0015){ref-type="ref-list"}             Median value (h) reported but not defined                                                                                               Median value (h) reported and defined as a temperature \< 37.5 °C on 2 successive readings                                                                             Median value (h) reported and defined as the time at which the blood films were negative for *P falciparum* for at least 8 hours                                                                                              Number of episodes (n/N) reported but not defined
  [Taylor 1998](#CD010678-bbs2-0016){ref-type="ref-list"}             Median value (h) reported and defined as time required for a child to achieve a Blantyre Coma Score of 5                                Median value (h) reported and defined as the time at which the rectal or axillary temperature dropped below 37.5 °C and remained \< 37.5 °C for 24 consecutive hours   Median value (h) reported and defined as the time at which the first of 2 negative (0 parasites/200 WBC) thick blood films was prepared. Every 4 hours till clearance                                                         Not reported
  [van Hensbroek 1996](#CD010678-bbs2-0017){ref-type="ref-list"}      Median value (h) reported and defined as time to regain full consciousness                                                              Median value (h) reported and defined as time needed for the rectal temperature to fall below 38.0 °C for at least 24 hours                                            Median value (h) reported and defined as time needed for all parasites to clear relative to parasite density at admission and assessed every 12 hours till clearance                                                          Number of episodes (n/N) reported and defined as a blood glucose level below 40 mg/dL (2.2 mmol/L)
  [Vinh 1997](#CD010678-bbs2-0018){ref-type="ref-list"}               Median value (h) reported and defined as time to regain full consciousness                                                              Median value (h) reported and defined as time for axillary temperature to fall ‒ and remain for ≥ 24 hours ‒ to 37.5 °C or lower                                       Median value (h) reported and defined as time to clear parasites                                                                                                                                                              Not reported
  [Walker 1993](#CD010678-bbs2-0019){ref-type="ref-list"}             Mean value (h) reported but not defined                                                                                                 Mean value (h) reported                                                                                                                                                Mean value (h) reported and defined as the time for parasitaemia to be cleared and to remain so up to Day 7. Assessed every 6 hours during period of coma and then every 12 hours.                                            Not reported
  ------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------

Abbreviations: WBC = white blood cell.

### Excluded studies {#CD010678-sec-0068}

We excluded 14 trials and listed the reasons for their exclusion in the '[Characteristics of excluded studies](#CD010678-sec-0127){ref-type="sec"}\' section.

Risk of bias in included studies {#CD010678-sec-0069}
--------------------------------

See [Figure 2](#CD010678-fig-0002){ref-type="fig"} for a summary of the 'Risk of bias\' assessments. We have presented further details in the [Characteristics of included studies](#CD010678-sec-0126){ref-type="sec"} tables.

![Risk of bias summary: review authors\' judgements about each risk of bias item for each included trial.](nCD010678-AFig-FIG02){#CD010678-fig-0002}

### Allocation {#CD010678-sec-0070}

Eight trials were at low risk of bias regarding the generation of allocation sequence while one trial was at high risk of bias ([Aguwa 2010](#CD010678-bbs2-0002){ref-type="ref-list"}). Ten trials were at unclear risk of bias because review authors did not provide enough information to permit us to make a judgement.

Eleven trials were at low risk of bias regarding allocation concealment and the remaining trials provided insufficient information to make a judgement.

### Blinding {#CD010678-sec-0071}

In all trials except [Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"} and [Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"}, investigators and participants were aware of treatment allocation. Participants were also not blind to the intervention as two different routes (intramuscular (artemether) and intravenous (quinine)) were used to administer the interventions. Blinding was unlikely to affect the assessment of the outcome 'death\' in all trials. In one trial, microscopists were blinded to the intervention and clinical status of the patients ([Huda 2003](#CD010678-bbs2-0005){ref-type="ref-list"}). The other subjective outcomes were thus at high risk of bias in all open included trials or at unclear risk of bias where trials did not provide information.

### Incomplete outcome data {#CD010678-sec-0072}

Fifteen trials reported no losses to follow‐up. The remaining four trials reported over 10% attrition in either one or both trial arms ([Seaton 1998](#CD010678-bbs2-0015){ref-type="ref-list"}; [Taylor 1998](#CD010678-bbs2-0016){ref-type="ref-list"}; [Satti 2002](#CD010678-bbs2-0014){ref-type="ref-list"}; [Aguwa 2010](#CD010678-bbs2-0002){ref-type="ref-list"}). Two trials used the 'per protocol\' number of participants as a denominator in the analysis ([Seaton 1998](#CD010678-bbs2-0015){ref-type="ref-list"}; [Taylor 1998](#CD010678-bbs2-0016){ref-type="ref-list"}). The other two trials used the number of participants randomized as the denominator in the analysis.

### Selective reporting {#CD010678-sec-0073}

We did not detect any evidence of selective outcome reporting based on comparison between the Methods section and results of the included studies.

### Other potential sources of bias {#CD010678-sec-0074}

We did not identify any other sources of bias.

Effects of interventions {#CD010678-sec-0075}
------------------------

See: [Table 1](#CD010678-tbl-0001){ref-type="table"}; [Table 2](#CD010678-tbl-0002){ref-type="table"}; [Table 3](#CD010678-tbl-0003){ref-type="table"}

### Artemether versus quinine {#CD010678-sec-0076}

#### Children {#CD010678-sec-0077}

Twelve trials were conducted in children; 11 in Africa and one in Asia. All used loading doses of quinine.

##### Death {#CD010678-sec-0078}

There was no overall difference in all‐cause mortality between intramuscular artemether and intravenous quinine (RR 0.97, 95% CI 0.77 TO 1.21; 1659 participants, 13 trials, I^2^ = 0%, [Analysis 1.1](#CD010678-fig-0004){ref-type="fig"}). However, these 13 trials were too small to detect or exclude clinically important differences, and the overall meta‐analysis remains significantly underpowered to prove equivalence (see [Table 4](#CD010678-tbl-0004){ref-type="table"} and [Table 5](#CD010678-tbl-0005){ref-type="table"}). The current total sample size has adequate power to exclude effects as large as seven extra deaths per 100 patients. [Adam 2002](#CD010678-bbs2-0001){ref-type="ref-list"} reported death within 24 hours. There was no difference between intramuscular artemether and intravenous quinine (RR 0.35, 95% CI 0.02 to 8.10; 41 participants, 1 trial, [Analysis 1.2](#CD010678-fig-0005){ref-type="fig"}).

##### Coma resolution time {#CD010678-sec-0079}

The mean coma resolution time was about five hours shorter with artemether (26 hours) compared with quinine (30.55 hours) (MD −5.45 hours, 95% CI −7.90 to −3.00; 358 participants, 6 trials, I^2^ = 0%, [Analysis 1.3](#CD010678-fig-0006){ref-type="fig"}). The results were not statistically significant when a sensitivity analysis excluding studies with unclear allocation concealment was done (MD −5.53 hours, 95% CI −12.39 to 1.33; 95 participants, 2 trials, [Analysis 3.3](#CD010678-fig-0021){ref-type="fig"}). In addition, three trials reported median time to coma resolution (see [Table 10](#CD010678-tbl-0010){ref-type="table"}). Two trials found no overall difference ([Murphy 1996](#CD010678-bbs2-0009){ref-type="ref-list"}; [Taylor 1998](#CD010678-bbs2-0016){ref-type="ref-list"}); and one trial found the median time to be longer with artemether (26 hours versus 20 hours, P = 0.046, [van Hensbroek 1996](#CD010678-bbs2-0017){ref-type="ref-list"}). Two other trials reported mean coma resolution time as mean (SD) but the data were not normally distributed and so we have reported this in an additional table ([Table 10](#CD010678-tbl-0010){ref-type="table"}) ([Minta 2005](#CD010678-bbs2-0008){ref-type="ref-list"}; [Osonuga 2009](#CD010678-bbs2-0012){ref-type="ref-list"}).

###### Additional data: Artemether versus quinine in children

  ---------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- ------------------------- ------------------ ------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------
  **Pre‐specified outcome**                                        **Trial reported outcome**                                       **Trial**                                                        **No. of participants**   **Artemether**     **Quinine**                          **Comparative results reported in article**

  Coma resolution time (hours)                                     Median\                                                          [Murphy 1996](#CD010678-bbs2-0009){ref-type="ref-list"}          160                       12  (2.8 to 96)    13  (2.8 to 96)                      Not significantly different
                                                                   (IQR)                                                                                                                                                                                                               

  Median\                                                          [van Hensbroek 1996](#CD010678-bbs2-0017){ref-type="ref-list"}   576                                                              26  (15 to 48)            20  (12 to 43)     P = 0.046                            
  (IQR)                                                                                                                                                                                                                                                                                

  Median\                                                          [Taylor 1998](#CD010678-bbs2-0016){ref-type="ref-list"}          164                                                              18  (8 to 30)             20  (10 to 54)     Not significantly different          
  (IQR)                                                                                                                                                                                                                                                                                

  Coma recovery (%) on Day 3                                       [Aguwa 2010](#CD010678-bbs2-0002){ref-type="ref-list"}           90                                                               15.9%                     21.4%              RR = 0.763 (95% CI 0.065 to 9.015)   

  Mean (SD)                                                        [Osonuga 2009](#CD010678-bbs2-0012){ref-type="ref-list"}         32                                                               4.5 (13.05)               9 (24.59)          P = 0.523                            

  Mean (SD)                                                        [Minta 2005](#CD010678-bbs2-0008){ref-type="ref-list"}           67                                                               30.57 (29.02)             25.15 (31.62)      P = 0.53                             

  Time to hospital discharge                                       \% spending less than one week in\                               [Aguwa 2010](#CD010678-bbs2-0002){ref-type="ref-list"}           90                        61.76%             71.74%                               P = 0.829
                                                                   hospital                                                                                                                                                                                                            

  Fever clearance (hours)                                          Median\                                                          [Murphy 1996](#CD010678-bbs2-0009){ref-type="ref-list"}          160                       32  (4 to 86)      32  (4 to 96)                        Not significantly different
                                                                   (IQR)                                                                                                                                                                                                               

  [van Hensbroek 1996](#CD010678-bbs2-0017){ref-type="ref-list"}   576                                                              30  (16 to 48)                                                   33  (12‐60)               P = 0.8                                                 

  [Taylor 1998](#CD010678-bbs2-0016){ref-type="ref-list"}          164                                                              31  (24 to 52)                                                   45  (33 to 60)            \"Significant\"                                         

  Fever clearance (%) on Day 3                                     [Aguwa 2010](#CD010678-bbs2-0002){ref-type="ref-list"}           90                                                               90.0%                     87.7%              P = 0.753                            

  Parasite clearance (hours)                                       Median\                                                          [Murphy 1996](#CD010678-bbs2-0009){ref-type="ref-list"}          160                       39.5  (24 to 45)   48\                                  P \< 0.001
                                                                   (IQR)                                                                                                                                                                          (37 to 56)                           

  [van Hensbroek 1996](#CD010678-bbs2-0017){ref-type="ref-list"}   576                                                              48  (36 to 60)                                                   60  (48 to 72)            P \< 0.001                                              

  [Taylor 1998](#CD010678-bbs2-0016){ref-type="ref-list"}          164                                                              32  (25 to 36)                                                   40  (32 to 48)            'significant\'                                          

  Parasite clearance (%) on Day 3                                  [Aguwa 2010](#CD010678-bbs2-0002){ref-type="ref-list"}           90                                                               99.0%\                    96.8%\             P = 0.422                            
                                                                                                                                                                                                     n = 44                    n = 46                                                  

  Needing blood transfusion                                        ‐                                                                [van Hensbroek 1996](#CD010678-bbs2-0017){ref-type="ref-list"}   ‐                         ‐                  ‐                                    \"The two groups were similar in terms of the need for blood transfusions,and the incidence of secondary bacterial infections (data not shown).\"
  ---------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- ------------------------- ------------------ ------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: IQR = interquartile range.

##### Neurological sequelae {#CD010678-sec-0080}

There was no statistically significant difference in the risk of neurological sequelae at hospital discharge between artemether (185 per 1000) and quinine (220 per 1000) (968 participants, 7 trials, I^2^ = 1%, [Analysis 1.4](#CD010678-fig-0007){ref-type="fig"}). Again these trials were too small to enable us to confidently detect or exclude what may be clinically important differences between treatments (see [Table 4](#CD010678-tbl-0004){ref-type="table"}). The overall meta‐analysis is adequately powered to exclude effects larger than eight additional sequelae per 100 patients.

Three trials continued to monitor patients with neurological sequelae after hospital discharge. [Satti 2002](#CD010678-bbs2-0014){ref-type="ref-list"} found no difference at day seven, [Taylor 1998](#CD010678-bbs2-0016){ref-type="ref-list"} found most sequelae had resolved and [van Hensbroek 1996](#CD010678-bbs2-0017){ref-type="ref-list"} found no difference at day 28 ([Analysis 1.5](#CD010678-fig-0008){ref-type="fig"}).

##### Parasite clearance time {#CD010678-sec-0081}

The mean parasite clearance time in children was approximately nine hours shorter with artemether (MD −9.03 hours, 95% CI −11.43 to −6.63; 420 participants, I^2^ = 62%, 7 trials, [Analysis 1.6](#CD010678-fig-0009){ref-type="fig"}). The results were similar after sensitivity analysis which excluded trials at unclear or high risk of selection bias. The mean parasite clearance times for artemether and quinine were 36.25 and 43.18 hours respectively.

Three additional trials reported median parasite clearance time and all showed an overall benefit with artemether (see [Table 10](#CD010678-tbl-0010){ref-type="table"}). Two trials expressed parasite clearance as the proportion of patients with parasite clearance at 72 hours and at seven days, with no overall differences between groups (see [Analysis 1.7](#CD010678-fig-0010){ref-type="fig"}) ([Ojuawo 1998](#CD010678-bbs2-0010){ref-type="ref-list"}; [Bobossi‐Serengbe 2015](#CD010678-bbs2-0003){ref-type="ref-list"}). The inconsistency may be due to trials differing with respect to the frequency with which they repeated malaria blood smears (see [Table 9](#CD010678-tbl-0009){ref-type="table"}).

##### Fever clearance time {#CD010678-sec-0082}

Eight trials reported mean fever clearance time with a statistically significant reduction of about three hours with artemether (MD −3.73 hours, 95% CI −6.55 to −0.92; 457 participants, 8 trials, I^2^ = 83%, [Analysis 1.8](#CD010678-fig-0011){ref-type="fig"}). The mean fever clearance times for artemether and quinine were 43.69 and 46.26 hours respectively. However, only two of the individual trials showed an overall difference between the groups. Three trials in children reported median fever clearance time and two trials found no overall difference between the two groups (see [Table 10](#CD010678-tbl-0010){ref-type="table"}). There was high inconsistency due to opposing directions of effect. Also, the definitions of fever varied across the included trials. Six trials used a cut‐off of body temperature less than 37.5 °C from initiation of treatment to define fever clearance (see [Table 9](#CD010678-tbl-0009){ref-type="table"}).

##### Need for blood transfusion {#CD010678-sec-0083}

One trial, [Olumese 1999](#CD010678-bbs2-0011){ref-type="ref-list"}, reported on the number of patients requiring blood transfusions for severe malarial anaemia in both artemether and quinine arms (RR 1.27, 95% CI 0.62 to 2.59; 103 participants, 1 trial, I^2^ = 0%, [Analysis 1.9](#CD010678-fig-0012){ref-type="fig"}). No statistically significant difference was observed between both arms.

##### Adverse effects {#CD010678-sec-0084}

Eight trials reported on the frequency of adverse events ([Walker 1993](#CD010678-bbs2-0019){ref-type="ref-list"}; [Murphy 1996](#CD010678-bbs2-0009){ref-type="ref-list"}; [van Hensbroek 1996](#CD010678-bbs2-0017){ref-type="ref-list"}; [Olumese 1999](#CD010678-bbs2-0011){ref-type="ref-list"}; [Adam 2002](#CD010678-bbs2-0001){ref-type="ref-list"}; [Huda 2003](#CD010678-bbs2-0005){ref-type="ref-list"}; [Minta 2005](#CD010678-bbs2-0008){ref-type="ref-list"}; [Bobossi‐Serengbe 2015](#CD010678-bbs2-0003){ref-type="ref-list"}). [Olumese 1999](#CD010678-bbs2-0011){ref-type="ref-list"} and [Huda 2003](#CD010678-bbs2-0005){ref-type="ref-list"} reported no adverse events had occurred during the trial duration (see [Table 11](#CD010678-tbl-0011){ref-type="table"}). One trial reported the absence of adverse events in the artemether arm ([Minta 2005](#CD010678-bbs2-0008){ref-type="ref-list"}). No trial reported discontinuation of medication.

###### Adverse event monitoring and reporting

  ---------------------------------------------------------------- ----------------- ---------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study ID**                                                     **Sample size**   **Clinical symptoms monitoring**                                                                                 **Biochemistry**                                                                                          **Haematological**                                   **Electrocardiogram**                                                                                               **Additional comments on adverse events**

  [Adam 2002](#CD010678-bbs2-0001){ref-type="ref-list"}            41                Not reported                                                                                                     Not reported                                                                                              Not reported                                         Not reported                                                                                                        \"Neurological deficits were not observed in any patient during the follow‐up period\"

  [Aguwa 2010](#CD010678-bbs2-0002){ref-type="ref-list"}           90                Not reported                                                                                                     Not reported                                                                                              Not reported                                         Not reported                                                                                                        None

  [Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"}            560               Clinical assessment every 4 hours for the first 24 hours and 6‐hourly afterwards                                 Blood glucose, lactate and cytokine levels measured 4, 8, 12 and 24 hours after admission                 Full blood count (FBC) on admission                  Pre‐treatment and 12 hours after initiation of treatment on Day 0, 4 hours after last dose and at discharge         None

  [Huda 2003](#CD010678-bbs2-0005){ref-type="ref-list"}            46                Lumbar puncture\                                                                                                 Blood Glucose, Renal Function Test,\                                                                      FBC on Days 0 and 3                                  Day 0                                                                                                               \"No serious side effects of either of the drugs were observed in our study\...\... Closer and more frequent monitoring and larger sample size would have probably revealed more subtle adverse drug effects.\"
                                                                                     Chest x‐ray on day 0                                                                                             Liver Function Test and Serum Electrolyte on Days 0 and 3                                                                                                                                                                                                                          

  [Karbwang 1992](#CD010678-bbs2-0006){ref-type="ref-list"}        26                Clinical evaluation daily for at least 7 days\                                                                   Biochemistry on Days 0, 2, 4 and 7                                                                        FBC on Days 0, 2, 4 and 7                            On admission for all patients; then once daily and every 6 hours for quinine and artemether patients respectively   \"The side effects in the quinine group were dizziness and vertigo. No side effects were detected with artemether\".
                                                                                     Lumbar puncture\                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                     Chest x‐ray on day 0                                                                                                                                                                                                                                                                                                                                                                                

  [Karbwang 1995](#CD010678-bbs2-0007){ref-type="ref-list"}        102               Clinical evaluation on admission and twice daily for at least 7 days\                                            Biochemistry on Days 0, 2, 4 and 7                                                                        FBC on Days 0, 2, 4 and 7                            On admission for all patients; then once daily and every 6 hours for quinine and artemether patients respectively   QTc prolongation and tinnitus were the major adverse events in Quinine arm.\
                                                                                     Lumbar puncture\                                                                                                                                                                                                                                                                                                                                                                                    Mild transient pain at injection site for approximately 15 mins after artemether treatment.
                                                                                     Chest x‐ray on day 0                                                                                                                                                                                                                                                                                                                                                                                

  [Minta 2005](#CD010678-bbs2-0008){ref-type="ref-list"}           67                Clinical examination daily on Days 1 to 7, and 14                                                                Blood glucose on Days 1, 2, 3, 5, 7 and 14\                                                               FBC on Days 1, 3, 5, 7 and 14                        Once daily on Days 1, 3, 5, 7 and 14                                                                                None
                                                                                                                                                                                                      Urea and Serum electrolyte, transaminases, phosphatases on Days 1, 3, 5, 7 and 14                                                                                                                                                                                                  

  [Murphy 1996](#CD010678-bbs2-0009){ref-type="ref-list"}          160               Clinical assessment on admission, then at 6‐, then 12‐hour intervals till discharge                              Blood glucose, urea, electrolytes, blood gases and when clinically indicated                              FBC on Day 0 and when clinically indicated\          On admission and at 6, 24, 30, 48 and 54 hours                                                                      None
                                                                                                                                                                                                                                                                                                                Blood cultures on Day 0                                                                                                                                                  

  [Ojuawo 1998](#CD010678-bbs2-0010){ref-type="ref-list"}          37                Clinical assessment on Day 0                                                                                     Urea and electrolyte\                                                                                     FBC on Day 0                                         None                                                                                                                None
                                                                                                                                                                                                      Blood sugar and liver function test on Day 0                                                                                                                                                                                                                                       

  [Olumese 1999](#CD010678-bbs2-0011){ref-type="ref-list"}         103               Clinical assessments on Days 0, 3, 7, 14, 28                                                                     Blood glucose, urea and creatinine, electrolytes on Days 0, 3, 7, 14, 28                                  WBC count on Days 0, 3, 7, 14, 28                    None                                                                                                                \"No adverse reactions to the two drugs were recorded during the study\".

  [Osonuga 2009](#CD010678-bbs2-0012){ref-type="ref-list"}         32                Clinical examination on Days 0 to 7 and 14                                                                       None                                                                                                      None                                                 None                                                                                                                None

  [Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"}             370               Clinical examination on admission\                                                                               Blood urea nitrogen, serum creatinine, aspartate aminotransferase, alanine transaminase, plasma lactate   FBC on admission                                     None                                                                                                                None
                                                                                     Chest x‐ray on admission\                                                                                                                                                                                                                                                                                                                                                                           
                                                                                     Lumbar puncture                                                                                                                                                                                                                                                                                                                                                                                     

  [Satti 2002](#CD010678-bbs2-0014){ref-type="ref-list"}           77                Clinical evaluation on admission and every six hours on Days 0 to 4, and then once daily on Days 14, 21 and 28   Blood glucose, serum creatinine, serum aspartate, aminotransferase on Day 0                               WBC, haemoglobin on Days 0 and 3                     None                                                                                                                None

  [Seaton 1998](#CD010678-bbs2-0015){ref-type="ref-list"}          33                Chest X‐ray on admission                                                                                         Renal and liver function tests on admission, Days 3 and 7                                                 FBC on Days 0, 3 and 7                               None                                                                                                                None

  [Taylor 1998](#CD010678-bbs2-0016){ref-type="ref-list"}          183               CSF collected on admission                                                                                       Blood glucose,\                                                                                           Haematocrit every 8 hours\                           On admission, 6, 48, 54 and 96 hours                                                                                \"Of the initial 127 patients on whom serial electrocardiographic tracings were made, more patients in the quinine group  showed prolongation of the corrected QT intervals after treatment, but the differences were not statistically or clinically significant.\"    \"There were no significant differences between the two treatment groups in terms of adverse effects associated with  antimalarial treatment (i.e. new signs and symptoms which develop within seven days of the start of treatment).\"
                                                                                                                                                                                                      Blood pH, on Day 0 (every four hours for the first 24 hours                                               FBC, urea, and electrolytes on Days 0, 3, 7 and 28                                                                                                                       

  [van Hensbroek 1996](#CD010678-bbs2-0017){ref-type="ref-list"}   576               Clinical examination on Day 0\                                                                                   Blood glucose on admission, after 4 hours and 12 hours                                                    PCV, haemoglobin, Blood culture on Day 0             None                                                                                                                None
                                                                                     Lumbar puncture on admission                                                                                                                                                                                                                                                                                                                                                                        

  [Vinh 1997](#CD010678-bbs2-0018){ref-type="ref-list"}            124               Clinical examination on admission                                                                                Blood glucose, serum creatinine, serum bilirubin on admission                                             FBC on admission                                     None                                                                                                                None

  [Walker 1993](#CD010678-bbs2-0019){ref-type="ref-list"}          54                Clinical examination twice daily\                                                                                Urea and Electrolyte, on days 3, 7, 14, 28                                                                PCV on days 3, 7, 14, 28                             On admission, at 4 and 6 hours                                                                                      None
                                                                                     Spinal taps                                                                                                                                                                                                                                                                                                                                                                                         
  ---------------------------------------------------------------- ----------------- ---------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CSF: cerebrospinal fluid; FBC: full blood count; PCV: packed cell volume; WBC: white blood cells

Only two trials reported episodes of hypoglycaemia ([Analysis 1.10](#CD010678-fig-0013){ref-type="fig"}). Two trials reported the proportion of participants with QT prolongation ([Minta 2005](#CD010678-bbs2-0008){ref-type="ref-list"}; [Murphy 1996](#CD010678-bbs2-0009){ref-type="ref-list"}). There was significantly higher proportion of QT prolongation in the artemether arm (RR 3.10, 95% CI 1.33 to 7.19; 229 participants, 2 trials, I^2^ = 52%, [Analysis 1.11](#CD010678-fig-0014){ref-type="fig"}). Both trials varied in terms of the populations studied. [Minta 2005](#CD010678-bbs2-0008){ref-type="ref-list"} had fever (38 °C or more) as part of the inclusion criteria. In addition, all participants received a single dose of oral SP in addition to either IM artemether or IV quinine. Other adverse effects reported were local skin reaction at the injection site, abscess, urticarial rash, pruritus, supraventricular tachycardia, urinary tract infection, and haemoglobinuria. However, these trials were insufficiently powered to detect differences in adverse events. The trials had similar definitions of adverse events (included only adverse effects that could not be attributable to malaria).

##### Time to hospital discharge {#CD010678-sec-0085}

None of the included trials reported time to discharge. One trial reported the proportion of patients that spent less than one week in hospital and found no significant difference between groups (see [Table 10](#CD010678-tbl-0010){ref-type="table"}).

#### Adults {#CD010678-sec-0086}

Four trials were conducted in adults: three in Asia and one in Oceania. All used loading doses of quinine.

##### Death {#CD010678-sec-0087}

Artemether resulted in fewer deaths compared with quinine (RR 0.59, 95% CI 0.42 to 0.83; 716 participants, 4 trials, I^2^ = 36%, [Analysis 1.1](#CD010678-fig-0004){ref-type="fig"}) from trials conducted mostly in Asia.

##### Coma resolution time {#CD010678-sec-0088}

Three trials reported a measure of coma resolution time. [Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"} reported median coma resolution time, which was shorter in the quinine arm. [Karbwang 1995](#CD010678-bbs2-0007){ref-type="ref-list"} found both arms to be comparable in terms of coma resolution time. The third trial, [Karbwang 1992](#CD010678-bbs2-0006){ref-type="ref-list"}, reported mean coma resolution time but the data were incompletely reported (see [Table 12](#CD010678-tbl-0012){ref-type="table"}).

###### Additional data: Artemether versus quinine in adults

  ------------------------------ ----------------------------------------------------------- ------------------------------------------------------- ------------------------- ----------------- ----------------------------- ---------------------------------------------
  **Pre‐specified outcome**      **Trial reported outcome**                                  **Trial**                                               **No. of participants**   **Artemether**    **Quinine**                   **Comparative results reported in article**
  Coma resolution time (hours)   Median (IQR)                                                [Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"}   560                       66 (30 to 132)    48 (20 to 84)                 P = 0.003
  Median (range)                 [Karbwang 1995](#CD010678-bbs2-0007){ref-type="ref-list"}   97                                                      48 (6 to 144)             48 (6 to 144)     Not significantly different   
  Fever clearance (hours)        Median (IQR)                                                [Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"}   560                       127 (60 to 216)   90 (54 to 144)                \< 0.001
  Median (range)                 [Seaton 1998](#CD010678-bbs2-0015){ref-type="ref-list"}     33                                                      32 (20 to 112)            48 (28 to 88)     P = 0.034                     
  Median (range)                 [Karbwang 1995](#CD010678-bbs2-0007){ref-type="ref-list"}   97                                                      79 (16 to 147)            84 (36 to 144)    Not significantly different   
  Parasite clearance (hours)     Median (IQR)                                                [Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"}   560                       72 (54 to 102)    90 (66 to 108)                \< 0.001
  Median (range)                 [Seaton 1998](#CD010678-bbs2-0015){ref-type="ref-list"}     33                                                      48(4 to 72)               52 (12 to112)     P = 0.381                     
  Median (range)                 [Karbwang 1995](#CD010678-bbs2-0007){ref-type="ref-list"}   97                                                      54 (30 to 164)            78 (18 to 168)    P = 0.007                     
  ------------------------------ ----------------------------------------------------------- ------------------------------------------------------- ------------------------- ----------------- ----------------------------- ---------------------------------------------

Abbreviations: IQR = interquartile range.

##### Neurological sequelae {#CD010678-sec-0089}

Only one trial reported neurological sequelae at discharge ([Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"}). Four neurological sequelae were reported with no difference between groups (560 participants, 1 trial, [Analysis 1.4](#CD010678-fig-0007){ref-type="fig"}).

##### Parasite clearance time {#CD010678-sec-0090}

One trial reported mean parasite clearance time but showed no overall difference between artemether and quinine (26 participants, one trial, [Analysis 1.6](#CD010678-fig-0009){ref-type="fig"}). Three other trials reported median parasite clearance time. Two trials reported a significantly shorter time to clearance of parasites with artemether ([Karbwang 1995](#CD010678-bbs2-0007){ref-type="ref-list"}; [Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"}; see [Table 10](#CD010678-tbl-0010){ref-type="table"}). [Seaton 1998](#CD010678-bbs2-0015){ref-type="ref-list"} found no significant difference between artemether and quinine with respect to parasite clearance time.

Trials differed with respect to the frequency with which they repeated malaria blood smears (see [Table 9](#CD010678-tbl-0009){ref-type="table"}).

##### Fever clearance time {#CD010678-sec-0091}

Four trials reported a measure of fever clearance time. [Karbwang 1992](#CD010678-bbs2-0006){ref-type="ref-list"} reported mean fever clearance time and found an overall reduction of about 30 hours with artemether (MD −29.7 hours, 95% CI −54.14 to −5.26; 26 participants, 1 trial, [Analysis 1.8](#CD010678-fig-0011){ref-type="fig"}). The other three trials in adults reported median fever clearance time; and two reported a statistically significant reduction in fever clearance time in favour of quinine and artemether respectively ([Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"}; [Seaton 1998](#CD010678-bbs2-0015){ref-type="ref-list"}). [Karbwang 1995](#CD010678-bbs2-0007){ref-type="ref-list"} found both groups were comparable (see [Table 12](#CD010678-tbl-0012){ref-type="table"}).

The definitions of fever varied across the included trials. Three trials used a cut‐off of body temperature less than 37.5 °C from initiation of treatment to define fever clearance (see [Table 9](#CD010678-tbl-0009){ref-type="table"}).

##### Need for blood transfusion {#CD010678-sec-0092}

One trial reported on the number of patients requiring blood transfusions for severe malarial anaemia in both artemether and quinine arms ([Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"}). No overall difference was observed between both arms (560 participants, one trial, [Analysis 1.9](#CD010678-fig-0012){ref-type="fig"}).

##### Adverse events {#CD010678-sec-0093}

One trial reported episodes of hypoglycaemia ([Analysis 1.10](#CD010678-fig-0013){ref-type="fig"}). Other adverse effects reported were abscess, induration at injection site, leg discomfort, chest infection and gastrointestinal bleeding. However, these trials were insufficiently powered to detect differences in adverse events. The trials had similar definitions of adverse events (included only adverse effects that could not be attributable to malaria).

#### Publication bias {#CD010678-sec-0094}

We constructed a funnel plot for trials that reported death ([Figure 3](#CD010678-fig-0003){ref-type="fig"}). Visual examination suggested the funnel plot is asymmetric due to the absence of smaller trials at the base. Asymmetry in the funnel plot could result from possible selection bias where smaller studies reporting greater treatment benefit for the experimental group were published (publication bias). The gap in the bottom corner of the graph suggests that smaller studies without statistically significant effects remain unpublished ([Higgins 2011](#CD010678-bbs2-0048){ref-type="ref-list"}).

![Funnel plot of comparison: 1 Artemether versus quinine, outcome: 1.1 Death.](nCD010678-AFig-FIG03){#CD010678-fig-0003}

### Artemether versus artesunate {#CD010678-sec-0095}

#### Adults {#CD010678-sec-0096}

Two trials, both from Asia, were conducted in adults.

##### Death {#CD010678-sec-0097}

Only two trials directly compared intramuscular artemether and intravenous artesunate. Overall, the risk of all‐cause mortality was higher following treatment with artemether (RR 1.80, 95% CI 1.09 to 2.97; 494 participants, 2 trials, [Analysis 2.1](#CD010678-fig-0015){ref-type="fig"}). However, both trials were too small to detect or exclude clinically important differences, and the overall meta‐analysis remains significantly underpowered to prove superiority (see [Table 4](#CD010678-tbl-0004){ref-type="table"} and [Table 5](#CD010678-tbl-0005){ref-type="table"}).

##### Coma resolution time {#CD010678-sec-0098}

Two trials reported median coma resolution times. Both trials reported a shorter coma resolution time with artesunate. However, these differences were not statistically significant ([Table 13](#CD010678-tbl-0013){ref-type="table"}).

###### Additional data: Artemether versus artesunate in adults

  ------------------------------ ------------------------------------------------------- ------------------------------------------------------ ---------------------------- ------------------------ ------------------------- ------------------------------- ---------------------------------------------
  **Pre‐specified outcome**      **Trial reported outcome**                              **Trial**                                              **Number of participants**   **Artemether**           **Artesunate IM**         **Artesunate IV**               **Comparative results reported in article**
  Coma resolution time (hours)   Median (range)                                          [Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"}   370                          72 (2 to 2232) n = 184   60 (4 to 2136), n = 186   ‐                               P = 0.11
  Median (95% CI)                [Vinh 1997](#CD010678-bbs2-0018){ref-type="ref-list"}   124                                                    47 (31 to 63)                30 (18 to 42)            24 (4 to 44)              ‐                               
  Fever clearance (hours)        Median (range)                                          [Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"}   370                          108 (0 to 888) n = 184   108 (0 to 888), n = 186   ‐                               P = 0.27
  Median (95% CI)                [Vinh 1997](#CD010678-bbs2-0018){ref-type="ref-list"}   124                                                    48 (38 to 58)                36 (30 to 42)            30 (18 to 42)             ‐                               
  Parasite clearance (hours)     Median (range)                                          [Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"}   370                          72 (2 to 204)            72 (7 to 330)             ‐                               P = 0.97
  Median (95% CI)                [Vinh 1997](#CD010678-bbs2-0018){ref-type="ref-list"}   124                                                    30 (26 to 34)                24 (15 to 33)            24 (15 to 33)             Not statistically significant   
  ------------------------------ ------------------------------------------------------- ------------------------------------------------------ ---------------------------- ------------------------ ------------------------- ------------------------------- ---------------------------------------------

Abbreviations: CI: confidence interval; IM: intramuscular; IV: intravenous.

##### Parasite clearance time {#CD010678-sec-0099}

Two trials found no overall difference in median parasite clearance time ([Vinh 1997](#CD010678-bbs2-0018){ref-type="ref-list"}; [Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"}).

##### Fever clearance time {#CD010678-sec-0100}

[Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"} found no statistically significant difference in median fever clearance time between intramuscular artemether and intravenous artesunate. The additional small trial found a benefit in favour of artesunate although this was not statistically significant ([Vinh 1997](#CD010678-bbs2-0018){ref-type="ref-list"}).

##### Need for blood transfusion {#CD010678-sec-0101}

[Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"} found no difference between treatments with respect to the need for blood transfusion in adult severe malaria patients (370 participants, one trial, [Analysis 2.2](#CD010678-fig-0016){ref-type="fig"}).

##### Adverse effects {#CD010678-sec-0102}

Only [Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"} reported adverse events. Overall, the risk of hypoglycaemia was higher in adults treated with intramuscular artemether compared with artesunate (RR 1.70, 95% CI 0.40 to 7.24; 370 participants, 1 trial, [Analysis 2.3](#CD010678-fig-0017){ref-type="fig"}).

Discussion {#CD010678-sec-0103}
==========

We present the main results of the review alongside a GRADE appraisal of the certainty of evidence in the 'Summary of findings\' tables ([Table 1](#CD010678-tbl-0001){ref-type="table"}; [Table 2](#CD010678-tbl-0002){ref-type="table"}; [Table 3](#CD010678-tbl-0003){ref-type="table"}).

Summary of main results {#CD010678-sec-0104}
-----------------------

We included 19 RCTs, enrolling 2874 children and adults with severe malaria. Twelve trials were conducted in Africa and seven trials were undertaken in Asia.

### Artemether versus quinine {#CD010678-sec-0105}

For children (trials mostly conducted in Africa), there is probably little or no difference in the risk of death between intramuscular artemether and quinine (moderate‐certainty evidence). Artemether may shorten the coma recovery time by about five hours (low‐certainty evidence), and makes little difference in the number of children with subsequent neurological sequelae (low‐certainty evidence). Artemether probably shortens the parasite clearance time by about nine hours (moderate‐certainty evidence), and may shorten the fever clearance time by about three hours (low‐certainty evidence).

For older children (\> 15 years) and adults in Asia, artemether probably reduces deaths compared with quinine (moderate‐certainty evidence), but larger trials are required to have full confidence in this finding.

### Artemether versus artesunate {#CD010678-sec-0106}

Artemether and artesunate have only been compared in two trials in adults from Asia, and mortality is probably higher with intramuscular artemether (moderate‐certainty evidence) but larger trials are required to have confidence in this finding.

Overall completeness and applicability of evidence {#CD010678-sec-0107}
--------------------------------------------------

Although 16 trials directly compared artemether versus quinine, none were adequately powered to detect clinically important differences. The total number of participants included in these trials (2375 participants) remains far short of the 7429 participants included in trials of artesunate versus quinine ([Sinclair 2012](#CD010678-bbs2-0063){ref-type="ref-list"}). The majority of data comparing artemether and quinine were from trials conducted in sub‐Saharan Africa where artemether is most widely used.

The two trials directly comparing artemether and artesunate were conducted in adults in Asia, and the results are therefore poorly applicable to children in Africa.

Artemether is prone to erratic and partial absorption and takes longer to achieve peak plasma concentrations, as demonstrated in animal and human studies ([Murphy 1997](#CD010678-bbs2-0057){ref-type="ref-list"}; [Hien 2004](#CD010678-bbs2-0047){ref-type="ref-list"}; [Mithwani 2004](#CD010678-bbs2-0056){ref-type="ref-list"}). These pharmacokinetic attributes make artemether that is injected intramuscularly less readily available in the human body and may explain the difference in outcomes between artesunate and intramuscular artemether we have observed in this review.

### Certainty of the evidence {#CD010678-sec-0108}

We assessed the certainty of the evidence using the GRADE approach and have presented it in three 'Summary of findings\' tables ([Table 1](#CD010678-tbl-0001){ref-type="table"}; [Table 2](#CD010678-tbl-0002){ref-type="table"}; [Table 3](#CD010678-tbl-0003){ref-type="table"}).

The evidence of equivalence between intramuscular artemether and intravenous quinine in children is of moderate certainty due to the small sample sizes of the included trials and the overall lack of power to fully exclude clinically important differences.

Similarly, we downgraded the certainty of the evidence for reductions in mortality in adults treated with artemether compared with quinine, and artesunate compared with artemether, to moderate certainty due to imprecision. Larger trials are needed to have full confidence in these effects.

Potential biases in the review process {#CD010678-sec-0109}
--------------------------------------

Our search strategy was comprehensive, and was without restrictions based on language, date of publication or publication status. We found several studies which mostly had small sample sizes and thus even the overall meta‐analysis was underpowered for several review outcomes. There was also a lack of direct evidence comparing artemether with artesunate. The findings of the funnel plot for death (Artemether versus quinine: [Figure 3](#CD010678-fig-0003){ref-type="fig"}) may suggest publication bias. However, asymmetry in the funnel plot may also be due to other reasons, such as poor methodological quality in smaller studies leading to spuriously inflated effects, true heterogeneity in the treatment effect, sampling variation, or chance ([Higgins 2011](#CD010678-bbs2-0048){ref-type="ref-list"}).

Agreements and disagreements with other studies or reviews {#CD010678-sec-0110}
----------------------------------------------------------

Some meta‐analyses and systematic reviews have evaluated the efficacy of artemether compared to quinine in treating severe malaria in children and adults. The earliest study was a meta‐analysis of randomized controlled trials ([Pittler 1999](#CD010678-bbs2-0060){ref-type="ref-list"}).

[Pittler 1999](#CD010678-bbs2-0060){ref-type="ref-list"} found no difference in deaths between intramuscular artemether and parenteral quinine in adults and children although there were fewer adverse effects associated with the administration of intramuscular artemether. [AQMSG 2001](#CD010678-bbs2-0038){ref-type="ref-list"} reported significantly fewer deaths and neurological sequelae with artemether compared to quinine. [PrayGod 2008](#CD010678-bbs2-0061){ref-type="ref-list"} found no difference in deaths, parasite clearance time, fever clearance time and neurological sequelae among children between artemether and quinine. However, the study found coma resolution time in children was faster with artemether compared to quinine.

Another systematic review concluded that artemether was not inferior to quinine for preventing death from cerebral malaria in children ([Kyu 2009](#CD010678-bbs2-0052){ref-type="ref-list"}). After the meta‐analyses and systematic reviews mentioned above, new clinical trials in which artemether has been compared with quinine and artesunate for the treatment of severe malaria in Africa and Asia have been published. However, no studies have compared artemether to artesunate in African children. These new studies are included in this Cochrane Review.

Authors\' conclusions {#CD010678-sec-0111}
=====================

Implications for practiceAlthough there is a paucity of direct evidence comparing artemether with artesunate, artemether is probably less effective than artesunate at preventing deaths from severe malaria. In circumstances where artesunate is not available, artemether is an alternative to quinine. Since 2015, the World Health Organization recommends intravenous or intramuscular artesunate over quinine for the treatment of severe malaria in adults and children. Artemether is also recommended in preference to quinine for the treatment of severe malaria where artesunate is not available.

Implications for researchLarger, adequately powered clinical trials are necessary for conclusive evidence on the relative effects of artemether. However, additional studies are unlikely given the current treatment recommendations.

What\'s new {#CD010678-sec-0118}
===========

**DateEventDescription**13 June 2019New citation required but conclusions have not changedThis is an update of a Cochrane Review. The conclusions remain the same as the last published version ([Esu 2014](#CD010678-bbs2-0073){ref-type="ref-list"})13 June 2019New search has been performedWe updated the literature search to 7 September 2018 and included one new study.

The Academic Editor of this review update was Professor Mical Paul.

We are grateful to David Sinclair for his help with the GRADE assessment in [Esu 2014](#CD010678-bbs2-0073){ref-type="ref-list"}. We also acknowledge Dr Amirhaobu Uwaoma\'s contributions to [Esu 2014](#CD010678-bbs2-0073){ref-type="ref-list"}.

The protocol for the original review was developed during the Reviews for Africa Fellowship Programme organized by the Nigerian Branch of the South Africa Cochrane Centre in July 2012 ([Esu 2013](#CD010678-bbs2-0072){ref-type="ref-list"}).

The editorial base of the Cochrane Infectious Diseases Group is funded by UK aid from the UK government for the benefit of low‐ and middle‐income countries (project number 300342‐104). The views expressed do not necessarily reflect the UK government's official policies.

**Search setCIDG SR^a^CENTRALMEDLINE^b^Embase^b^LILACS^b^ISI Web of Science**1malariaMalaria ti, ab, MeSHMalaria ti, ab, MeSHMalaria ti, ab, Emtreemalariamalaria2artemetherArtemether ti, abArtemether ti, abArtemether ti, ab, Emtreeartemetherartemether3Artemisinin\*Artemisinin\* ti, abArtemisinin\* ti, abArtemisinin\* ti, abArtemisinin\*Artemisinin\*4intramuscularIntramuscular ti, abIntramuscular ti, abIntramuscular ti, abintramuscularintramuscular5parenteralInjections, Intramuscular \[MeSH\]Injections, Intramuscular \[MeSH\]Intramuscular drug administration \[Emtree\]parenteralparenteral62 or 3Parenteral ti, abParenteral ti, abParenteral drug administration \[Emtree\]2 or 32 or 374 or 52 or 32 or 32 or 34 or 54 or 581 and 5 and 74 or 5 or 64 or 5 or 64 or 5 or 61 and 5 and 71 and 5 and 79‐1 and 7 and 81 and 7 and 81 and 7 and 8‐Randomised clinical trial\*10‐‐‐‐‐8 and 9

^a^Cochrane Infectious Diseases Group Specialized Register.  ^b^Search terms used in combination with the search strategy for retrieving trials developed by the Cochrane Collaboration ([Lefebvre 2011](#CD010678-bbs2-0053){ref-type="ref-list"}).

###### Artemether versus quinine

  Outcome or subgroup title                                                         No. of studies   No. of participants   Statistical method                    Effect size
  --------------------------------------------------------------------------------- ---------------- --------------------- ------------------------------------- --------------------------
  [1 Death](#CD010678-fig-0004){ref-type="fig"}                                     17                                     Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  1.1 Children                                                                      13               1659                  Risk Ratio (M‐H, Fixed, 95% CI)       0.97 \[0.77, 1.21\]
  1.2 Adults                                                                        4                716                   Risk Ratio (M‐H, Fixed, 95% CI)       0.59 \[0.42, 0.83\]
  [2 Death: Time since admission to hospital](#CD010678-fig-0005){ref-type="fig"}   1                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  2.1 Death within 24 hours                                                         1                41                    Risk Ratio (M‐H, Fixed, 95% CI)       0.35 \[0.02, 8.10\]
  [3 Coma resolution time (hours)](#CD010678-fig-0006){ref-type="fig"}              6                                      Mean Difference (IV, Fixed, 95% CI)   Subtotals only
  3.1 Children                                                                      6                358                   Mean Difference (IV, Fixed, 95% CI)   ‐5.45 \[‐7.90, ‐1.00\]
  [4 Neurological sequelae at discharge](#CD010678-fig-0007){ref-type="fig"}        8                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  4.1 Children                                                                      7                968                   Risk Ratio (M‐H, Fixed, 95% CI)       0.84 \[0.66, 1.07\]
  4.2 Adults                                                                        1                560                   Risk Ratio (M‐H, Fixed, 95% CI)       2.92 \[0.31, 27.86\]
  [5 Neurological sequelae at follow‐up](#CD010678-fig-0008){ref-type="fig"}        2                566                   Risk Ratio (M‐H, Fixed, 95% CI)       0.82 \[0.49, 1.38\]
  5.1 Day 7                                                                         1                134                   Risk Ratio (M‐H, Fixed, 95% CI)       0.76 \[0.27, 2.14\]
  5.2 Day 28                                                                        1                432                   Risk Ratio (M‐H, Fixed, 95% CI)       0.84 \[0.46, 1.53\]
  [6 Parasite clearance time](#CD010678-fig-0009){ref-type="fig"}                   8                446                   Mean Difference (IV, Fixed, 95% CI)   ‐8.82 \[‐11.20, ‐6.45\]
  6.1 Children                                                                      7                420                   Mean Difference (IV, Fixed, 95% CI)   ‐9.03 \[‐11.43, ‐6.63\]
  6.2 Adults                                                                        1                26                    Mean Difference (IV, Fixed, 95% CI)   1.70 \[‐15.56, 18.96\]
  [7 Proportion with parasite clearance](#CD010678-fig-0010){ref-type="fig"}        2                498                   Risk Ratio (M‐H, Fixed, 95% CI)       0.95 \[0.91, 1.00\]
  7.1 At 72 hours                                                                   2                249                   Risk Ratio (M‐H, Fixed, 95% CI)       0.92 \[0.84, 1.02\]
  7.2 At 7 days                                                                     2                249                   Risk Ratio (M‐H, Fixed, 95% CI)       0.98 \[0.95, 1.02\]
  [8 Fever clearance time (hours)](#CD010678-fig-0011){ref-type="fig"}              9                                      Mean Difference (IV, Fixed, 95% CI)   Subtotals only
  8.1 Children                                                                      8                457                   Mean Difference (IV, Fixed, 95% CI)   ‐3.73 \[‐6.55, ‐0.92\]
  8.2 Adults                                                                        1                26                    Mean Difference (IV, Fixed, 95% CI)   ‐29.70 \[‐54.14, ‐5.26\]
  [9 Need for blood transfusion](#CD010678-fig-0012){ref-type="fig"}                2                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  9.1 Children                                                                      1                103                   Risk Ratio (M‐H, Fixed, 95% CI)       1.27 \[0.62, 2.59\]
  9.2 Adults                                                                        1                560                   Risk Ratio (M‐H, Fixed, 95% CI)       0.97 \[0.73, 1.29\]
  [10 Episodes of hypoglycaemia](#CD010678-fig-0013){ref-type="fig"}                3                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  10.1 Children                                                                     2                617                   Risk Ratio (M‐H, Fixed, 95% CI)       0.68 \[0.44, 1.05\]
  10.2 Adults                                                                       1                560                   Risk Ratio (M‐H, Fixed, 95% CI)       0.44 \[0.30, 0.64\]
  [11 Adverse events](#CD010678-fig-0014){ref-type="fig"}                           7                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  11.1 QT prolongation                                                              2                229                   Risk Ratio (M‐H, Fixed, 95% CI)       3.10 \[1.33, 7.19\]
  11.2 Local skin reactions                                                         1                576                   Risk Ratio (M‐H, Fixed, 95% CI)       0.12 \[0.03, 0.50\]
  11.3 Abscess                                                                      2                1136                  Risk Ratio (M‐H, Fixed, 95% CI)       0.20 \[0.04, 0.90\]
  11.4 Urticarial rash                                                              1                576                   Risk Ratio (M‐H, Fixed, 95% CI)       0.33 \[0.01, 8.15\]
  11.5 Supraventricular tachycardia                                                 1                54                    Risk Ratio (M‐H, Fixed, 95% CI)       0.23 \[0.01, 4.59\]
  11.6 Pruritus                                                                     1                67                    Risk Ratio (M‐H, Fixed, 95% CI)       0.34 \[0.01, 8.13\]
  11.7 Urinary tract infection                                                      1                54                    Risk Ratio (M‐H, Fixed, 95% CI)       3.46 \[0.15, 81.36\]
  11.8 Induration at injection site                                                 1                33                    Risk Ratio (M‐H, Fixed, 95% CI)       15.44 \[0.94, 253.49\]
  11.9 Leg discomfort                                                               1                560                   Risk Ratio (M‐H, Fixed, 95% CI)       0.69 \[0.22, 2.16\]
  11.10 Chest infection                                                             1                560                   Risk Ratio (M‐H, Fixed, 95% CI)       1.11 \[0.81, 1.53\]
  11.11 GI bleeding                                                                 1                560                   Risk Ratio (M‐H, Fixed, 95% CI)       0.79 \[0.52, 1.20\]
  11.12 Haemoglobinuria                                                             1                212                   Risk Ratio (M‐H, Fixed, 95% CI)       0.09 \[0.00, 1.56\]

![Analysis\
Comparison 1 Artemether versus quinine, Outcome 1 Death.](nCD010678-CMP-001-01){#CD010678-fig-0004}

![Analysis\
Comparison 1 Artemether versus quinine, Outcome 2 Death: Time since admission to hospital.](nCD010678-CMP-001-02){#CD010678-fig-0005}

![Analysis\
Comparison 1 Artemether versus quinine, Outcome 3 Coma resolution time (hours).](nCD010678-CMP-001-03){#CD010678-fig-0006}

![Analysis\
Comparison 1 Artemether versus quinine, Outcome 4 Neurological sequelae at discharge.](nCD010678-CMP-001-04){#CD010678-fig-0007}

![Analysis\
Comparison 1 Artemether versus quinine, Outcome 5 Neurological sequelae at follow‐up.](nCD010678-CMP-001-05){#CD010678-fig-0008}

![Analysis\
Comparison 1 Artemether versus quinine, Outcome 6 Parasite clearance time.](nCD010678-CMP-001-06){#CD010678-fig-0009}

![Analysis\
Comparison 1 Artemether versus quinine, Outcome 7 Proportion with parasite clearance.](nCD010678-CMP-001-07){#CD010678-fig-0010}

![Analysis\
Comparison 1 Artemether versus quinine, Outcome 8 Fever clearance time (hours).](nCD010678-CMP-001-08){#CD010678-fig-0011}

![Analysis\
Comparison 1 Artemether versus quinine, Outcome 9 Need for blood transfusion.](nCD010678-CMP-001-09){#CD010678-fig-0012}

![Analysis\
Comparison 1 Artemether versus quinine, Outcome 10 Episodes of hypoglycaemia.](nCD010678-CMP-001-10){#CD010678-fig-0013}

![Analysis\
Comparison 1 Artemether versus quinine, Outcome 11 Adverse events.](nCD010678-CMP-001-11){#CD010678-fig-0014}

###### Artemether versus artesunate

  Outcome or subgroup title                                            No. of studies   No. of participants   Statistical method                Effect size
  -------------------------------------------------------------------- ---------------- --------------------- --------------------------------- ---------------------
  [1 Death](#CD010678-fig-0015){ref-type="fig"}                        2                                      Risk Ratio (M‐H, Fixed, 95% CI)   Subtotals only
  1.1 Adults                                                           2                494                   Risk Ratio (M‐H, Fixed, 95% CI)   1.80 \[1.09, 2.97\]
  [2 Need for blood transfusion](#CD010678-fig-0016){ref-type="fig"}   1                                      Risk Ratio (M‐H, Fixed, 95% CI)   Subtotals only
  2.1 Adults                                                           1                370                   Risk Ratio (M‐H, Fixed, 95% CI)   1.01 \[0.78, 1.32\]
  [3 Episodes of hypoglycaemia](#CD010678-fig-0017){ref-type="fig"}    1                                      Odds Ratio (M‐H, Fixed, 95% CI)   Totals not selected
  [4 Adverse events](#CD010678-fig-0018){ref-type="fig"}               1                                      Risk Ratio (M‐H, Fixed, 95% CI)   Totals not selected
  4.1 Spontaneous bleeding                                             1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]

![Analysis\
Comparison 2 Artemether versus artesunate, Outcome 1 Death.](nCD010678-CMP-002-01){#CD010678-fig-0015}

![Analysis\
Comparison 2 Artemether versus artesunate, Outcome 2 Need for blood transfusion.](nCD010678-CMP-002-02){#CD010678-fig-0016}

![Analysis\
Comparison 2 Artemether versus artesunate, Outcome 3 Episodes of hypoglycaemia.](nCD010678-CMP-002-03){#CD010678-fig-0017}

![Analysis\
Comparison 2 Artemether versus artesunate, Outcome 4 Adverse events.](nCD010678-CMP-002-04){#CD010678-fig-0018}

###### Artemether versus quinine (sensitivity analysis)

  Outcome or subgroup title                                                         No. of studies   No. of participants   Statistical method                    Effect size
  --------------------------------------------------------------------------------- ---------------- --------------------- ------------------------------------- -------------------------
  [1 Death](#CD010678-fig-0019){ref-type="fig"}                                     6                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  1.1 Children                                                                      5                898                   Risk Ratio (M‐H, Fixed, 95% CI)       1.04 \[0.78, 1.37\]
  1.2 Adults                                                                        1                560                   Risk Ratio (M‐H, Fixed, 95% CI)       0.74 \[0.50, 1.11\]
  [2 Death: Time since admission to hospital](#CD010678-fig-0020){ref-type="fig"}   1                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  2.1 Death within 24 hours                                                         1                41                    Risk Ratio (M‐H, Fixed, 95% CI)       0.35 \[0.02, 8.10\]
  [3 Coma resolution time (hours)](#CD010678-fig-0021){ref-type="fig"}              2                                      Mean Difference (IV, Fixed, 95% CI)   Subtotals only
  3.1 Children                                                                      2                95                    Mean Difference (IV, Fixed, 95% CI)   ‐5.53 \[‐12.39, 1.33\]
  [4 Neurological sequelae at discharge](#CD010678-fig-0022){ref-type="fig"}        4                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  4.1 Children                                                                      3                634                   Risk Ratio (M‐H, Fixed, 95% CI)       0.77 \[0.58, 1.01\]
  4.2 Adults                                                                        1                560                   Risk Ratio (M‐H, Fixed, 95% CI)       2.92 \[0.31, 27.86\]
  [5 Neurological sequelae at follow‐up](#CD010678-fig-0023){ref-type="fig"}        2                566                   Risk Ratio (M‐H, Fixed, 95% CI)       0.82 \[0.49, 1.38\]
  5.1 Day 7                                                                         1                134                   Risk Ratio (M‐H, Fixed, 95% CI)       0.76 \[0.27, 2.14\]
  5.2 Day 28                                                                        1                432                   Risk Ratio (M‐H, Fixed, 95% CI)       0.84 \[0.46, 1.53\]
  [6 Parasite clearance time](#CD010678-fig-0024){ref-type="fig"}                   3                162                   Mean Difference (IV, Fixed, 95% CI)   ‐7.73 \[‐12.65, ‐2.80\]
  6.1 Children                                                                      3                162                   Mean Difference (IV, Fixed, 95% CI)   ‐7.73 \[‐12.65, ‐2.80\]
  [7 Fever clearance time (hours)](#CD010678-fig-0025){ref-type="fig"}              3                                      Mean Difference (IV, Fixed, 95% CI)   Subtotals only
  7.1 Children                                                                      3                162                   Mean Difference (IV, Fixed, 95% CI)   ‐4.03 \[‐10.05, 1.99\]
  [8 Need for blood transfusion](#CD010678-fig-0026){ref-type="fig"}                1                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  8.1 Adults                                                                        1                560                   Risk Ratio (M‐H, Fixed, 95% CI)       0.97 \[0.73, 1.29\]
  [9 Episodes of hypoglycaemia](#CD010678-fig-0027){ref-type="fig"}                 3                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  9.1 Children                                                                      2                617                   Risk Ratio (M‐H, Fixed, 95% CI)       0.68 \[0.44, 1.05\]
  9.2 Adults                                                                        1                560                   Risk Ratio (M‐H, Fixed, 95% CI)       0.44 \[0.30, 0.64\]
  [10 Adverse events](#CD010678-fig-0028){ref-type="fig"}                           7                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  10.1 QT prolongation                                                              2                229                   Risk Ratio (M‐H, Fixed, 95% CI)       3.10 \[1.33, 7.19\]
  10.2 Local skin reactions                                                         1                576                   Risk Ratio (M‐H, Fixed, 95% CI)       0.12 \[0.03, 0.50\]
  10.3 Abscess                                                                      2                1136                  Risk Ratio (M‐H, Fixed, 95% CI)       0.20 \[0.04, 0.90\]
  10.4 Urticarial rash                                                              1                576                   Risk Ratio (M‐H, Fixed, 95% CI)       0.33 \[0.01, 8.15\]
  10.5 Supraventricular tachycardia                                                 1                54                    Risk Ratio (M‐H, Fixed, 95% CI)       0.23 \[0.01, 4.59\]
  10.6 Pruritus                                                                     1                67                    Risk Ratio (M‐H, Fixed, 95% CI)       0.34 \[0.01, 8.13\]
  10.7 Urinary tract infection                                                      1                54                    Risk Ratio (M‐H, Fixed, 95% CI)       3.46 \[0.15, 81.36\]
  10.8 Induration at injection site                                                 1                33                    Risk Ratio (M‐H, Fixed, 95% CI)       15.44 \[0.94, 253.49\]
  10.9 Leg discomfort                                                               1                560                   Risk Ratio (M‐H, Fixed, 95% CI)       0.69 \[0.22, 2.16\]
  10.10 Chest infection                                                             1                560                   Risk Ratio (M‐H, Fixed, 95% CI)       1.11 \[0.81, 1.53\]
  10.11 GI bleeding                                                                 1                560                   Risk Ratio (M‐H, Fixed, 95% CI)       0.79 \[0.52, 1.20\]
  10.12 Haemoglobinuria                                                             1                212                   Risk Ratio (M‐H, Fixed, 95% CI)       0.09 \[0.00, 1.56\]
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###### Artemether versus artesunate (sensitivity analysis)

  Outcome or subgroup title                                            No. of studies   No. of participants   Statistical method                Effect size
  -------------------------------------------------------------------- ---------------- --------------------- --------------------------------- ---------------------
  [1 Death](#CD010678-fig-0029){ref-type="fig"}                        2                                      Risk Ratio (M‐H, Fixed, 95% CI)   Subtotals only
  1.1 Adults                                                           2                494                   Risk Ratio (M‐H, Fixed, 95% CI)   1.80 \[1.09, 2.97\]
  [2 Need for blood transfusion](#CD010678-fig-0030){ref-type="fig"}   1                                      Risk Ratio (M‐H, Fixed, 95% CI)   Subtotals only
  2.1 Adults                                                           1                370                   Risk Ratio (M‐H, Fixed, 95% CI)   1.01 \[0.78, 1.32\]
  [3 Episodes of hypoglycaemia](#CD010678-fig-0031){ref-type="fig"}    1                                      Risk Ratio (M‐H, Fixed, 95% CI)   Totals not selected
  [4 Adverse events](#CD010678-fig-0032){ref-type="fig"}               1                                      Risk Ratio (M‐H, Fixed, 95% CI)   Totals not selected
  4.1 Spontaneous bleeding                                             1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
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Characteristics of included studies \[ordered by study ID\] {#CD010678-sec-0126}
===========================================================

[Adam 2002](#CD010678-bbs2-0001){ref-type="ref-list"}MethodsTrial design: open label RCT  Trial dates: November 2001 to January 2002ParticipantsNumber of participants: 41 children enrolled  Inclusion criteria: children with severe malaria (age range not stated); cerebral malaria; repeated convulsions; severe anaemia with haemoglobin \< 5g/dL; hyperparasitaemia (parasite count \> 100,000 rings/µL); or combinations of these criteria.\
Exclusion criteria: none statedInterventionsIntramuscular artemether (Kunming Pharmaceuticals; China)Loading dose of 3.2 mg/kg on day 1\...\...followed by 1.6 mg/kg once daily for the following 4 daysIntravenous quinineLoading dose of 20 mg/kg of quinine dihydrochloride in 10 mL/kg 5% dextrose over 4 hours\...\...followed by 10 mg/kg of quinine dihydrochloride in 10 mL/kg 5% dextrose solution over 4 hours, every 8 hours for at least 72 hours\...\...followed by oral quinine (for 7 days as soon as patient could tolerate).OutcomesOutcomes included in the review:\
DeathComa resolution timeParasite clearance timeFever clearance timeEpisodes of hypoglycaemia\
Outcomes not included in the review:\
Gametocyte carriageRecrudescenceNotesLocation: Outpatient clinic in New Halfa, Eastern Sudan  Transmission: \"meso‐endemic\"\
Funding: none stated***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"Each child was randomized\". No further details provided.Allocation concealment (selection bias)Low risk\"Envelopes containing the assigned treatment were opened sequentially at the time when each patient was recruited to the study\".Blinding (performance bias and detection bias)   Objective outcome: DeathLow riskDescribed as open‐label. However, lack of blinding is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias)   Subjective outcomes: OthersHigh riskAn open‐label trial.Incomplete outcome data (attrition bias)   All outcomesLow riskNo losses to follow‐up were reported.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[Aguwa 2010](#CD010678-bbs2-0002){ref-type="ref-list"}MethodsTrial design: RCT\
Trial dates: July to October 2007ParticipantsNumber of participants: 90 children enrolled\
Inclusion criteria: children between 6 months and 12 years of age presenting with fever (\> 37.5 °C ) and *P falciparum* infection with 1 or more general danger signs of severe or complicated malaria based on the WHO criteria for severe malaria.\
Exclusion criteria: serious concomitant illness (for example, sickle cell anaemia, HIV, tuberculosis and other chronic diseases); severe malnutrition; known hypersensitivity to 1 of the trial drugs.InterventionsIntramuscular artemether (Paluther; May and Baker)Loading dose of 3.2 mg/kg on admission\...\...followed by 1.6 mg/kg once daily for 2 days.Intravenous or intramuscular quinine (Quinimax; Sanofi)Loading dose 20 mg salt/kg body weight on admission\...\...followed by 10 mg/kg every 8 hours; the infusion rate did not exceed 5 mg salt/kg per hourOutcomesOutcomes included in the review:\
DeathProportion of children recovered from coma on day 3Proportion of children discharged by day 7Proportion of children with fever clearance on day 3 and day 14Proportion of children with parasite clearance on day 3 and day 14\
Outcomes not included in the review:\
Hospital bed‐daysNotesLocation: Federal Medical Centre, Birnin Kudu, Jigawa State of Nigeria\
Transmission: stable perennial transmission\
Funding: none stated***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High risk\"Patients were assigned to receive quinine if the last digit of their hospital identification number was odd and to receive artemether if the last digit of their hospital identification number was even or zero\".Allocation concealment (selection bias)High riskTrial authors did not describe any methods of allocation concealment, and this would not be possible using this randomization method.Blinding (performance bias and detection bias)   Objective outcome: DeathLow riskNo blinding was described. However, lack of blinding is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias)   Subjective outcomes: OthersHigh riskNo blinding is described, and blinding would not be feasible.Incomplete outcome data (attrition bias)   All outcomesHigh riskLosses to follow‐up at day 14 were \> 10% in both trial arms.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[Bobossi‐Serengbe 2015](#CD010678-bbs2-0003){ref-type="ref-list"}MethodsTrial design: randomized trial\
Trial dates: June to August 2010ParticipantsNumber of participants: 212 hospitalized children\
Inclusion criteria: children between 6 and 59 months with clinical signs of severe malaria; *P falciparum* infection; and informed consent from parents or guardians.\
Exclusion criteria: children with known hypersensitivity to quinine.InterventionsIntramuscular artemetherLoading dose of 2 mg/kg on admission at 12 hour intervals\...\...followed by 2 mg/kg once daily for 2 days.Intravenous quinineLoading dose 10 mg salt/kg body weight on admission\...\...followed by 10 mg/kg every 4 hours for 3 days\...\...then oral quinine continued until the 7th day.OutcomesOutcomes included in the review:\
DeathProportion with parasitaemia on day 3 and day 7Adverse events\
Outcomes not included in the review: noneNotesLocation: Bangui Pediatric Complex, Bangui, Central African Republic\
Transmission: stable perennial transmission\
Funding: not stated***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskWeb‐based block randomization used.Allocation concealment (selection bias)Unclear riskNot stated.Blinding (performance bias and detection bias)   Objective outcome: DeathLow riskNot stated. However, lack of blinding is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias)   Subjective outcomes: OthersHigh riskNo blinding is described, and blinding would not be feasible as the route of administration is different for artemether and quinine.Incomplete outcome data (attrition bias)   All outcomesLow riskNo losses to follow‐up reported.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[Hien 1996](#CD010678-bbs2-0004){ref-type="ref-list"}MethodsTrial design: double‐blind RCT\
Trial dates: not statedParticipantsNumber of participants: 560 adults aged 15 to 79 years enrolled\
Inclusion criteria: patients were included in the trial if they:\
(or an accompanying relative) gave informed consent;had asexual forms of *P falciparum* on a peripheral‐blood smear;were older than 14 years;were not in the first trimester of pregnancy;were not intravenous drug users;had received less than 3 g of quinine or 2 doses of artemisinin or a derivative in the previous 48 hours;and had 1 or more of the following:a score on the Glasgow Coma Scale of less than 11 (indicating cerebral malaria);anaemia (hematocrit, 20 percent), with a parasite count exceeding 100,000 parasites/mm³ on a peripheral blood smear;jaundice (serum bilirubin, 2.5 mg/dL (50 mmol per litre)), with a parasite count of more than 100,000 parasites/mm³ on a peripheral blood smear;renal impairment (urine output, 400 mL per 24 hours; and serum creatinine, 3 mg/dL (250 mmol/L));hypoglycaemia (blood glucose, 40 mg/dL (2.2 mmol/L));hyperparasitaemia (10% parasitaemia);systolic blood pressure below 80 mmHg with cool extremities (indicating shock).\
Exclusion criteria: none statedInterventionsIntramuscular artemether (Kunming Pharmaceutical)Loading dose of 4 mg/kg\...\...followed by 2 mg/kg 8‐hourly for a minimum of 3 days\...\...followed by either a single oral dose of 15 mg of mefloquine or oral dose of 10 mg quinine sulphate for up to 4 days.Intramuscular quinineLoading dose of 20 mg/kg\...\...followed by 10 mg/kg per kilogram 8‐hourly\...\...followed by either a single oral dose of 15 mg/kg mefloquine or oral dose of 10 mg/kg quinine sulphate for up to 4 daysOutcomesOutcomes included in the review:\
DeathComa resolution timeNeurological sequelaeFever clearance timeParasite clearance timeHypoglycaemiaNeed for blood transfusionAdverse effects\
Outcomes not included in the review:\
Duration of parenteral antimalarial treatmentTime for plasma lactate level to fall below 2.5 mmol/LNotesLocation: Special Research Ward, Centre for Tropical Diseases, Ho Chi Minh City, Vietnam\
Transmission: not stated\
Funding: Wellcome Trust***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskTrial authors provided no information on methods of sequence generation.Allocation concealment (selection bias)Low risk\"The drugs for each patient were placed in a coded sealed envelope and the envelopes were randomized in blocks of 20. Once a patient was enrolled in the study the envelope was opened\".Blinding (performance bias and detection bias)   Objective outcome: DeathLow risk\"To maintain blinding, a separate team of nurses, who were not otherwise involved with the care of the study patients, drew up and gave the injections. The drugs were kept in an opaque packet in a locked cabinet during the study\".\
Both interventions were administered by intramuscular injection so blinding was feasible.Blinding (performance bias and detection bias)   Subjective outcomes: OthersLow risk\"To maintain blinding, a separate team of nurses, who were not otherwise involved with the care of the study patients, drew up and gave the injections. The drugs were kept in an opaque packet in a locked cabinet during the study\".\
Both interventions were administered by intramuscular injection so blinding was feasible.Incomplete outcome data (attrition bias)   All outcomesLow riskNo losses to follow‐up were recorded.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[Huda 2003](#CD010678-bbs2-0005){ref-type="ref-list"}MethodsTrial design: open RCT\
Trial dates: April 2000 to July 2001ParticipantsNumber: 46 children aged 6 months to 12 years enrolled\
Inclusion criteria:\
Asexual forms of *P falciparum* from peripheral blood smear;1 or more clinical manifestations of severe malaria present which included:cerebral malaria;severe anaemia (haemoglobin \< 5 g/dL or hematocrit \< 15%);metabolic abnormalities (hypoglycaemia: plasma glucose \< 40 mg/dL or \< 2.2 mmol/L);algid malaria (associated with peripheral circulatory failure or shock);blackwater fever;renal failure;spontaneous bleeding (thrombocytopenia, DIC);pulmonary oedema;jaundice.\
Exclusion criteria:\
History of having received artemether/quinine within 24 hours preceding admission.Severe protein energy malnutrition.Clinical/laboratory evidence of other significant illness not attributable to severe malaria.InterventionsIntramuscular artemetherLoading dose of 1.6 mg/kg twice a day on admission\...\...followed by 1.6 mg/kg once a day for 5 days.Intravenous quinineLoading dose of 20 mg/kg\...\...followed by 10 mg/kg every 8 hours by infusion\...\...followed by oral quinine sulphate once the patient was conscious, for a total period of 7 days.\
Supportive therapy was given to all patients.OutcomesOutcomes included in the review:\
DeathParasite clearance timeFever resolution timeComa recovery\
Outcomes not included in the review: noneNotesLocation: Inpatient Unit of Department of Pediatrics, and Parasitology laboratory, Department of Microbiology, Uttar Pradesh, India\
Transmission: unknown\
Funding: none stated***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskTrial authors provided no information on methods of sequence generation.Allocation concealment (selection bias)Unclear riskTrial authors provided no information on allocation concealment.Blinding (performance bias and detection bias)   Objective outcome: DeathLow riskAn open‐label trial is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias)   Subjective outcomes: OthersLow risk\"The slides for malarial parasites were transported to the parasitology laboratory where the person examining the slides was unaware of the clinical status of the patient and also the treatment assignment group\".Incomplete outcome data (attrition bias)   All outcomesLow riskNo losses to follow‐up were recorded.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[Karbwang 1992](#CD010678-bbs2-0006){ref-type="ref-list"}MethodsTrial design: RCT\
Trial dates: May to December 1991ParticipantsNumber of participants: 26 adults aged 15 to 45 years enrolled\
Inclusion criteria: patients with severe *P falciparum* malaria (WHO definition) with no history of antimalarials within 24 hours prior to admission, aged between 15 to 45 years and weighed 45 to 60 kg\
Exclusion criteria: none statedInterventionsIntramuscular artemether (Arthermin®)Loading dose of 160 mg\...\...followed by 80 mg once daily for 6 daysIntravenous quinineLoading dose of 20 mg/kg\...\...followed by 10 mg/kg 8‐hourly for 7 days\...\...followed by quinine sulphate tablets as soon as oral medication was possible.OutcomesOutcomes included in the review:\
DeathComa resolution timeNeurological sequelaeFever clearance timeParasite clearance timeAdverse effects\
Outcomes not included in the review:\
Survival rateCause of deathNotesLocation: Prapokklao Hospital, Chantaburi, Thailand\
Transmission: not stated\
Funding: support from United Medical Ltd., Bangkok (provided artemether)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"The patients were randomized to receive either quinine or artemether\".Allocation concealment (selection bias)Unclear riskTrial authors provided no information on allocation concealment.Blinding (performance bias and detection bias)   Objective outcome: DeathLow riskTrial authors provided no information on blinding.\
However, lack of blinding is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias)   Subjective outcomes: OthersHigh riskTrial authors provided no information on blinding, however it may not be feasible due to different routes of administration for both interventions.Incomplete outcome data (attrition bias)   All outcomesLow riskNo losses to follow‐up reported.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[Karbwang 1995](#CD010678-bbs2-0007){ref-type="ref-list"}MethodsTrial design: RCT\
Trial dates:1992 to 1994ParticipantsNumber of participants: 102 adults aged between 15 and 55 years enrolled\
Inclusion criteria: male and non‐pregnant female patients with severe *P falciparum* malaria (WHO definition) with no history of antimalarial treatment within 24 hours before admission aged 15 to 65 years and weighing 45 to 75 kg\
Exclusion criteria: patients with concurrent diseases were excludedInterventionsIntramuscular artemetherLoading dose of 160 mg\...\...followed by 80 mg once daily for 6 days.Intravenous quinineLoading dose of 20 mg/kg\...\...followed by 10 mg/kg 8‐hourly for 7 days\...\...followed by quinine sulphate tablets as soon as oral medication was possible.OutcomesOutcomes included in the review:\
DeathComa resolution timeNeurological sequelaeFever clearance timeParasite clearance timeAdverse effects\
Outcomes not included in the review:\
Survival rateNotesLocation: Prapokklao Hospital, Chantaburi, Thailand\
Transmission: not stated\
Funding: UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskCentral randomization at WHO Office.Allocation concealment (selection bias)Low risk\"Each treatment was enclosed in a sealed envelope, which was opened only after the physician in charge had decided to recruit the patient into the study\".Blinding (performance bias and detection bias)   Objective outcome: DeathLow riskTrial authors provided no information on blinding.\
However, lack of blinding is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias)   Subjective outcomes: OthersHigh riskTrial authors provided no information on blinding; however it might not have been feasible due to different routes of administration for both interventions.Incomplete outcome data (attrition bias)   All outcomesLow riskLoss to follow‐up about 5%.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[Minta 2005](#CD010678-bbs2-0008){ref-type="ref-list"}MethodsTrial design: open RCT\
Trial dates: June 1993 to February 1994 and June 1994 to December 1994ParticipantsNumber of participants: 67 children aged 3 months to 15 years enrolled\
Inclusion criteria: fever (core temperature ≥ 38 °C); positive blood smear for *P falciparum* with ≥ 0.1% of parasitized erythrocytes; 1 major criterion or 2 minor criteria for severe malaria cases (WHO criteria); and parental consent\
Exclusion criteria: children with infection who had been treated within 24 hours with quinine or intramuscular injection were not eligible.InterventionsIntramuscular artemether (Paluther)Loading dose of 3.2 mg/kg on admission (2 times)\...\...followed by 1.6 mg/kg once daily for 4 days.Intravenous quinineLoading dose of 20 mg/kg on admission\...\...followed by 10 mg/kg every 8 hours until oral drug administration was possible (10 mg/kg every 8 hours).OutcomesOutcomes included in the review:\
DeathComa resolution timeFever clearanceParasite clearanceAdverse events\
Outcomes not included in the review:\
RecrudescenceNotesLocation: Gabriel Touré\'s Hospital, Mali\
Transmission: unknown\
Funding: Rhône‐Poulenc Rorer Doma (France)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskCentral randomization by clinical monitor.Allocation concealment (selection bias)Low riskOpaque envelopes used to conceal allocation.Blinding (performance bias and detection bias)   Objective outcome: DeathLow riskAn open‐label trial is unlikely to bias an objective outcome like death.\
No blinding is described, and blinding would not be feasible.Blinding (performance bias and detection bias)   Subjective outcomes: OthersHigh riskAn open‐label trial.Incomplete outcome data (attrition bias)   All outcomesLow riskNo losses to follow‐up reported.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[Murphy 1996](#CD010678-bbs2-0009){ref-type="ref-list"}MethodsTrial design: open RCT\
Trial dates: not statedParticipantsNumber: 160 children aged 5 months to 12 years enrolled\
Inclusion criteria: children were admitted to the trial if they had *P falciparum* asexual parasitaemia; were comatose; and parental consent was obtained.\
Exclusion criteria: children were excluded if there was evidence of a pre‐existing neurological deficit; head injury; or history of recent treatment with antimalarial drugs other than chloroquine.InterventionsIntramuscular artemether (Paluther, Rhône‐Poulenc)Loading dose of 3.2 mg/kg\...\...followed by 1.6 mg/kg once daily; at least 3 doses of artemether were given\...\...followed by sulphadoxine‐pyrimethamine if parasitaemia had cleared and the child could drink. Otherwise artemether was continued for a total of 5 days (4 maintenance doses)Intravenous quinine (Laboratoires Renaudin, Paris)Loading dose of 20 mg/kg infused over 4 hours\...\...followed by 10 mg/kg every 8 hours with dose given over 2 hours. At least 3 doses of parenteral quinine were given, and continued until the child was able to drink and parasitaemia had cleared\...\...then a single dose of sulphadoxine‐pyrimethamine (sulphadoxine 25 mg/kg, pyrimethamine 1.25 mg/kg) given orally or intramuscularly.OutcomesOutcomes included in the review:\
Time to deathComa resolutionNeurological sequelaeFever clearanceParasite clearanceAdverse effects\
Outcomes not included in the review:\
Mortality with respiratory distressNotesLocation: Kenya Medical Research Institute (KEMRI) Coastal Research Unit, Kilifi district hospital, Kenya.\
Transmission: unknown\
Funding:\
KEMRIUNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)The Wellcome Trust***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskCentrally‐coded unique trial numbers.Allocation concealment (selection bias)Low riskSealed envelopes prepared by the clinical monitor.Blinding (performance bias and detection bias)   Objective outcome: DeathLow riskAn open‐label trial is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias)   Subjective outcomes: OthersHigh riskAn open‐label trial.\
Blinding unlikely as artemether and quinine were given by 2 different routes.Incomplete outcome data (attrition bias)   All outcomesLow risk40 patients (14 from artemether arm and 26 from quinine arm) excluded (mostly for not meeting inclusion criteria).Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[Ojuawo 1998](#CD010678-bbs2-0010){ref-type="ref-list"}MethodsTrial design: RCT\
Trial dates: not statedParticipantsNumber of participants: 37 children enrolled (age range not stated)\
Inclusion criteria: Children with unrousable coma, asexual forms of *P falciparum* parasitaemia and no other identifiable cause of coma.\
Exclusion criteria: none statedInterventionsIntramuscular artemetherLoading dose of 3.2 mg/kg on admission\...\...followed by 1.6 mg/kg 12 hours later\...\...then 1.6 mg/kg once daily for 2 daysIntravenous quinineLoading dose of 10 mg/kg infused over 2 hours\...\...followed by 10 mg/kg every 8 hours until patient regained consciousness\...then switched to oral dose for a total of 7 daysOutcomesOutcomes included in the review:\
DeathComa resolution timeNeurologic sequelaeFever clearance timePercentage of children with parasites clearance at days 3 and 7\
Outcomes not included in the review: noneNotesLocation: University of Ilorin Teaching Hospital, Nigeria\
Transmission: unknown\
Funding: none stated***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"Patients were randomly assigned to either of the two treatment modalities\".Allocation concealment (selection bias)Unclear riskInsufficient information about the sequence generation process to permit judgement.Blinding (performance bias and detection bias)   Objective outcome: DeathLow riskUnlikely to be biased whether blinding was done or not.Blinding (performance bias and detection bias)   Subjective outcomes: OthersHigh riskNo information about blinding provided by trial authors.\
Blinding unlikely as artemether and quinine were given by 2 different routes.Incomplete outcome data (attrition bias)   All outcomesLow riskNo losses to follow‐up recorded.Selective reporting (reporting bias)Low riskMost relevant outcomes reported.Other biasLow riskNo other bias identified.[Olumese 1999](#CD010678-bbs2-0011){ref-type="ref-list"}MethodsTrial design: open label RCT\
Trial dates: not statedParticipantsNumber of participants: 103 children aged 11 months to 5 years enrolled\
Inclusion criteria: Children aged 6 months to 5 years satisfying the WHO criteria for cerebral malaria, viz. unrousable coma lasting more than 30 minutes (with or without convulsions) with the presence of peripheral *P falciparum* parasitaemia were included in the trial.\
Exclusion criteria: none statedInterventionsIntramuscular artemetherLoading dose of 3.2 mg/kg on admission\...\...followed by 1.6 mg/kg once daily for 4 daysIntravenous quinine (Lemquine®)Loading dose of 20 mg/kg infused over 4 hours\...\...followed by 10 mg/kg infused over 2 hours given every 8 hours until the patient is conscious and oral quinine continued at 10 mg/kg orally every 8 hours to complete a total of 21 doses or 7 days\
Loading dose quinine was omitted in patients with a positive history of quinine or mefloquine ingestion in the preceding 24 hours before hospital presentation.OutcomesOutcomes included in the review:\
DeathParasite clearance timeFever clearance timeSurvival and neurological symptomsComa recovery timeNeurological deficitsBlood transfusions\
Outcomes not included in the review:\
Time to full ambulationNotesLocation: Emergency Paediatric ward, University College Hospital, Ibadan, Nigeria\
Transmission: unknown\
Funding: World Bank/UNDP/WHO special fund for Research and Training in Tropical Diseases (TDR)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated allocation.Allocation concealment (selection bias)Unclear riskMethods not described by trial authors.Blinding (performance bias and detection bias)   Objective outcome: DeathLow riskUnlikely to be biased whether blinding was done or not.Blinding (performance bias and detection bias)   Subjective outcomes: OthersHigh riskNo information of blinding reported by authors.\
Blinding unlikely as artemether and quinine were given by 2 different routes.Incomplete outcome data (attrition bias)   All outcomesLow riskNo losses to follow‐up recorded.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[Osonuga 2009](#CD010678-bbs2-0012){ref-type="ref-list"}MethodsTrial design: RCT\
Trial dates: not statedParticipantsNumber: 32 children aged 1 to 12 years enrolled\
Inclusion criteria: children aged 1 to 12 years, with fever (temperature \> 37.5 °C), presence of convulsion, vomiting, hypoglycaemia, anaemia and headache. Informed consent obtained from the parents and guardians. Assurance that patients will be resident within catchments of trial for follow‐up. Absence of concomitant illness such as bronchopneumonia, typhoid, meningitis, urinary tract infection.\
Exclusion criteria: history of blood transfusion in the last 2 months, presence of concomitant illness, history of previous allergy to quinine and artemether.InterventionsIntramuscular artemether (Rhône‐Poulence, Rorer France)Loading dose of 1.6 mg/kg twice on day 0\...\...followed by 1.6 mg/kg once daily for the next 4 daysIntravenous quinine (Evans)Loading dose of 10 mg/kg infused over 4 hours\...\...followed by 10 mg/kg given at 8‐hour intervals and oral quinine (10 mg/kg body weight, 8‐hour intervals) as soon as the patient\'s condition allowed.\
Treatment with quinine was for a total of 7 days.OutcomesOutcomes included in the review:\
Coma resolution timeFever clearance timeParasite clearance time\
Outcomes not included in the review: noneNotesLocation: Overcomers Specialist Clinic Ileshan and General Hospital Ikenne, Nigeria\
Transmission: unknown\
Funding: none stated***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"The children were randomly allocated into 2 treatment groups; treatment Q and A for quinine and artemether respectively\".Allocation concealment (selection bias)Unclear riskNo information on allocation concealment provided by trial authors.Blinding (performance bias and detection bias)   Objective outcome: DeathLow riskUnlikely to be biased whether blinding was done or not.Blinding (performance bias and detection bias)   Subjective outcomes: OthersHigh riskNo information of blinding reported by authors.\
Blinding unlikely as artemether and quinine were given by 2 different routes.Incomplete outcome data (attrition bias)   All outcomesLow riskAttrition about 6% and not likely to affect outcomes.Selective reporting (reporting bias)Low riskNo evidence of selective reporting. Authors have published 3 outcomes in 3 different publications from the same trial.Other biasLow riskNo other bias identified.[Phu 2010](#CD010678-bbs2-0013){ref-type="ref-list"}MethodsTrial design: double‐blind RCT\
Trial dates: May 1996 to June 2003ParticipantsNumber of participants: 370 adults aged between 15 and 77 years enrolled\
Inclusion criteria: peripheral blood smears had asexual forms of *P falciparum* and had at least 1 of the following severe complications:\
cerebral malaria (Glasgow Coma Score was less than 11);renal acute failure (oliguria and serum creatinine \> 250 μmol/L);jaundice (total serum bilirubin \> 50 μmol/L) with a parasite count of more than 100,000/μL or with serum creatinine \> 250 μmol/L;hypoglycaemia (blood glucose \< 2.2 mmol/L);anaemia (haematocrit \< 20%) with a parasite count of more than 100,000/μL;hyperparasitaemia (parasite count \> 500,000/μL);hyperlactataemia (plasma lactate \> 4 mmol/L);metabolic acidosis (standard base excess ≥ 5 mmol/L, base deficit \< 10 mmol/L);shock (systolic blood pressure \< 80 mmHg with cool extremities).\
Exclusion criteria: patients were not included if they were \< 14 years, were pregnant in the first trimester, were known intravenous drug abusers, had received more than 3 g of quinine or 2 doses of any artemisinin derivatives in the previous 48 hours before admission, had a past history of allergy to any artemisinin derivatives, or if known to be HIV positive.InterventionsIntramuscular artemether (Kunming Pharmaceutical Company, Kunming, China)Loading dose of 3.2 mg/kg\...\...followed by 1.6 mg/kg daily for at least 2 days.Intramuscular artesunate (Guilin No 2 Pharmaceutical Factory, Guangxi, China)Loading dose of 2.4 mg/kg on admission\...\...followed by 1.2 mg/kg once daily for at least 2 days\...\...followed by 2 mg/kg of oral artesunate to complete a total of 7 days.OutcomesOutcomes included in the review:\
DeathComa resolution timeTime to dischargeFever clearance timeParasite clearance timeEpisodes of hypoglycaemiaAdverse effects\
Outcomes not included in the review:\
Time to drinkingTime to eatingTime to sittingTime to standingTime to walkingNotesLocation: Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam\
Transmission: not stated\
Funding: Wellcome Trust, UK***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"The randomization was generated from random number tables\".Allocation concealment (selection bias)Low risk\"Labels with the name of drug for each patient were put in coded sealed opaque envelopes, and the envelopes were randomized in blocks of 20. Once a patient was enrolled in the study the envelope was opened\".Blinding (performance bias and detection bias)   Objective outcome: DeathLow risk\"An independent team of nurses, not otherwise involved in the study or responsible for the care of these patients, open the envelope, randomized the patient and prepared the injection. Neither the treating physicians, study doctors and nurses, or patients knew which anti‐malarial drugs was administered\".Blinding (performance bias and detection bias)   Subjective outcomes: OthersLow risk\"An independent team of nurses, not otherwise involved in the study or responsible for the care of these patients, open the envelope, randomized the patient and prepared the injection. Neither the treating physicians, study doctors and nurses, or patients knew which anti‐malarial drugs was administered\".Incomplete outcome data (attrition bias)   All outcomesLow riskNo loss to follow‐up recorded.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[Satti 2002](#CD010678-bbs2-0014){ref-type="ref-list"}MethodsTrial design: RCT\
Trial dates: May 1995 to June 1996ParticipantsNumber: 77 children enrolled aged 3 months to 15 years\
Inclusion criteria: children who satisfied the WHO criteria for diagnosis of cerebral malaria (such as unrousable coma for at least 30 minutes following convulsions, positive blood film for malaria, exclusion of other causes of encephalopathy); and informed consent by parent or guardian.\
Exclusion criteria: concomitant acute illness such as pneumonia, meningitis or acute renal failure and any contraindication to IM injection.InterventionsIntramuscular artemetherLoading dose of 1.6 mg/kg, repeated after 12 hours\...\...followed by 1.6 mg/kg once daily for 4 days.Intravenous quinineLoading dose of 10 mg/kg\...\...followed by 10 mg/kg repeated every 8 hours and changed to oral dose when patient was able to drink.\
Treatment with quinine was for a total of 7 days.OutcomesOutcomes included in the review:\
DeathComa resolution timeNeurological sequelaeFever clearance timeParasite clearance time\
Outcomes not included in the review:\
28th‐day cure rateNotesLocation: Khartoum Children\'s Emergency Hospital and Ahmed Gasim Specialist Hospital for Children, Sudan\
Transmission: unknown\
Funding:\
Danish Development Agency (DANIDA)German Academic Exchange Service (DAAD)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"The cases were randomly allocated into two groups\".Allocation concealment (selection bias)Unclear riskNo information provided by trial authors about allocation concealment.Blinding (performance bias and detection bias)   Objective outcome: DeathLow riskUnlikely to be biased whether blinding was done or not.Blinding (performance bias and detection bias)   Subjective outcomes: OthersHigh riskNo information of blinding reported by authors.\
Blinding unlikely as artemether and quinine were given by 2 different routes.Incomplete outcome data (attrition bias)   All outcomesHigh riskMore than 10% of participants in each arm dropped out before day 28.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[Seaton 1998](#CD010678-bbs2-0015){ref-type="ref-list"}MethodsTrial design: open‐label RCT\
Trial dates: June 1992 to May 1995ParticipantsNumber: 33 adults aged above 12 years\
Inclusion criteria: blood smear showed asexual forms of *P falciparum*; in addition to fulfilling 1 or more of the WHO criteria for severe or complicated malaria.\
Exclusion criteria: patients under the age of 12 years, pregnant women, those who had received parenteral antimalarial treatment prior to admission and those with a co‐existent bacterial, viral, fungal or mixed malarial infection.InterventionsIntramuscular artemether (Rhone‐Poulenc Rorer)Loading dose of 3.2 mg/kg\...\...followed by 1.6 mg/kg once daily for 4 days.Intravenous quinine (Medipharma)Loading dose of 20 mg/kg\...\...followed by 10 mg/kg 8‐hourly and patients able to tolerate oral medication were switched to oral quinine after 48 hours to complete a total of 7 days.OutcomesOutcomes included in the review:\
DeathComa resolution timeFever clearance timeParasite clearance timeEpisodes of hypoglycaemiaAdverse effects\
Outcomes not included in the review: noneNotesLocation: Port Moresby General Hospital, Papua New Guinea\
Transmission: seasonal/sporadic\
Funding:\
UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)Colt FoundationWellcome Trust***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskPatients were randomly assigned to treatment with quinine or artemether.Allocation concealment (selection bias)Low riskEnvelopes containing the assigned treatment were opened sequentially when a patient was recruited.Blinding (performance bias and detection bias)   Objective outcome: DeathLow riskUnlikely to be biased whether blinding was done or not.Blinding (performance bias and detection bias)   Subjective outcomes: OthersHigh riskNo information of blinding reported by authors.\
Blinding unlikely as artemether and quinine were given by 2 different routes.Incomplete outcome data (attrition bias)   All outcomesHigh riskDifferential proportion of withdrawals from both arms (25% versus 10%).Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[Taylor 1998](#CD010678-bbs2-0016){ref-type="ref-list"}MethodsTrial design: open label RCT\
Trial dates: January 1992 to June 1994ParticipantsNumber: 183 children enrolled (age range not stated)\
Inclusion criteria: children with asexual forms of *P falciparum* detected in a peripheral blood smear, and a Blantyre Coma Score ≤ 2, and if no other cause of fever or altered consciousness could be discovered.\
Exclusion criteria: none statedInterventionsIntramuscular artemetherLoading dose of 3.2 mg/kg on admission\...\...followed by 1.6 mg/kg once daily; a minimum of 3 doses were given\...\...then oral sulphadoxine‐pyrimethamine (approximately 25 mg/kg sulphadoxine and 1.25 mg/kg pyrimethamine) if parasitaemia had cleared and the patient was fully conscious.Intravenous quinineLoading dose of 20 mg/kg infused over 4 hours\...\...followed by 10 mg/kg infused over 2 hours at 8‐hour intervals. After a minimum of 3 intravenous quinine doses, oral quinine given in 10 mg/kg doses at 8‐hour intervals if the patient was able to drink\...\...then oral sulphadoxine‐pyrimethamine (same as above).OutcomesOutcomes included in the review:\
DeathComa resolution timeNeurological sequelaeFever clearance timeParasite clearance time\
Outcomes not included in the review:\
Recurrent parasitaemiaReticulocyte responseNotesLocation: Paediatric ward at the Queen Elizabeth Central Hospital, Malawi\
Transmission: unknown\
Funding: UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR).***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskBlock randomization.Allocation concealment (selection bias)Low risk\"Randomized treatment assignments were prepared in blocks of ten by the sponsoring agency. Following initial stabilization, diagnosis and examination, a sealed envelope containing the treatment group was opened, and the patient was allocated to treatment\".Blinding (performance bias and detection bias)   Objective outcome: DeathLow riskAn open‐label trial is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias)   Subjective outcomes: OthersHigh riskAn open‐label trial.Incomplete outcome data (attrition bias)   All outcomesHigh riskDifferential proportion of withdrawals from both arms (13% versus 8%).Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[van Hensbroek 1996](#CD010678-bbs2-0017){ref-type="ref-list"}MethodsTrial design: open‐label trial\
Trial dates: 1992 to 1994ParticipantsNumber: 576 children aged 1 to 9 years enrolled\
Inclusion criteria: unconscious children 1 to 9 years of age with a Blantyre coma score of 2 or less, asexual forms of *P falciparum* identified on a thick blood film, and a parent or guardian gave informed consent.\
Exclusion criteria: patients with diseases other than malaria at the time of admission and those who recovered consciousness immediately after correction of hypoglycaemia or within 1 hour if they were convulsing on admission. Patients treated with quinine before admission.InterventionsIntramuscular artemether (Paluther, Rhone‐Poulenc)Loading dose of 3.2 mg/kg on admission\...\...followed by daily doses of 1.6 mg/kg for 3 days.Intravenous quinine (Rotexmedica, Germany)Loading dose of 20 mg/kg\...\...followed by 10 mg/kg every 12 hours\...\...then oral quinine (once patient was able to swallow) for a total of 5 days.\
An oral dose of approximately 1.25 mg/kg pyrimethamine and 25 mg/kg sulfadoxine was given to both arms to reduce recrudescence (in the 2nd and 3rd years of the trial).OutcomesOutcomes included in the review:\
DeathComa resolution timeNeurological sequelae at dischargeNeurological sequelae at 28 daysFever clearance timeParasite clearance timeAdverse effects\
Outcomes not included in the review:\
Residal neurological sequelae (5 months\' follow‐up)28th day cure rateNotesLocation: Royal Victoria Hospital and Sibanor Health Centre, Banjul, Gambia\
Transmission: unknown\
Funding:\
UNDP/World Bank/WHO special programme for research and training in tropical diseases (TDR)The Netherlands Foundation for the Advancement of Tropical ResearchThe Ter Meulen FoundationThe Medical Research Council***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskTrial authors do not provide details of sequence generation.Allocation concealment (selection bias)Low risk\"The treatment code for each child was stored in a sealed envelope that was opened after the admission procedure was completed and parental consent had been obtained\".Blinding (performance bias and detection bias)   Objective outcome: DeathLow riskAn open‐label trial is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias)   Subjective outcomes: OthersLow risk\"Each blood film was examined by two independent observers who were unaware of the treatment code\".Incomplete outcome data (attrition bias)   All outcomesLow riskNo losses to follow‐up were recorded.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[Vinh 1997](#CD010678-bbs2-0018){ref-type="ref-list"}MethodsTrial design: open RCT\
Trial dates: March 1992 to September 1994ParticipantsNumber: 124 adults aged between 16 and 66 years\
Inclusion criteria: 15 years of age or older, with clinical symptoms and signs of malaria and the presence of asexual forms of *P falciparum* in their peripheral blood. In addition, having at least 1 of the following signs:\
unrousable coma (Glasgow Coma Score \< 3);hypoglycaemia (blood glucose \< 2.2 mmol/L (40 mg %);acute renal failure (plasma creatinine \> 265.2 µmol/L (3 mg %) with or without oliguria);jaundice (total bilirubin \> 51.3 mol/L (3 mg %)) with parasitaemia \> 100,000/µL or with plasma creatinine \>1.5 mg %;anaemia (haematocrit \< 20%) with parasitaemia \> 100,000/µL;shock (systolic arterial pressure \< 80 mmHg with a thready pulse and cold clammy extremities);hyperparasitaemia \>500,000/µL.\
Exclusion criteria: patients were excluded from the trial if prior treatment with more than 3 g of quinine or 2 doses of artemisinin or a derivative had been recorded by the peripheral health care worker. Pregnant patients in the first trimester, and patients with concomitant diseases (such as active tuberculosis, bacterial meningitis), or mixed infections with *P vivax* were also excluded from the trial.InterventionsIntramuscular artemether (Kunming Pharmaceutical, Yunnan, China)Loading dose of 200 mg\...\...followed by 100 mg once daily for 3 days.Intramuscular artesunate (Guilin No. 2 Pharmaceutical Factory, Guangxi, China)Loading dose of 120 mg\...\...followed by 60 mg once daily for 3 days.Intravenous artesunate (Guilin No. 2 Pharmaceutical Factory, Guangxi, China)Loading dose of 120 mg\...\...followed by 60 mg once daily for 3 days.\
All patients received 750 mg mefloquine (Lariam®, Roche) as a single dose after regaining consciousness or at day 4.OutcomesOutcomes included in the review:\
DeathComa resolution timeFever clearance timeParasite clearance time\
Outcomes not included in the review:\
Fatality rateNotesLocation: Tan Phu Regional Hospital, Vietnam\
Transmission: endemic\
Funding: Roche Asian Research Foundation, Hong Kong***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskTrial authors do not provide details about random sequence generation.Allocation concealment (selection bias)Low risk\"When a patient fulfilled the enrolment criteria, a sealed envelope containing the code for the treatment regimen was opened to allocate him/her to one of the following 4 treatment groups\".Blinding (performance bias and detection bias)   Objective outcome: DeathLow riskDescribed as open‐label. However, lack of blinding is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias)   Subjective outcomes: OthersHigh riskAn open‐label trial.Incomplete outcome data (attrition bias)   All outcomesLow riskNo losses to follow‐up were reported.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[Walker 1993](#CD010678-bbs2-0019){ref-type="ref-list"}MethodsTrial design: open RCT\
Trial dates: not statedParticipantsNumber: 54 children aged 1 to 5 years enrolled\
Inclusion criteria: patients were admitted if they satisfied the strict WHO definition of cerebral malaria.\
Exclusion criteria: none statedInterventionsIntramuscular artemetherLoading dose of 3.2 mg/kg on admission\...\...followed by 1.6 mg/kg for 4 days.Intravenous quinineLoading dose of 20 mg/kg infused over 4 hours on admission\...\...followed by 10 mg/kg every 8 hours until patient regained consciousness\...\...then oral medication was continued at 10 mg/kg, every 8 hours for a total of 7 days.OutcomesOutcomes included in the review:\
DeathComa resolution timeNeurological sequelaeFever clearance timeParasite clearance timeAdverse effects\
Outcomes not included in the review:\
Time to sit unaidedTime to drinkDischarge packed cell volumeMortality rate28th‐day cure rateParasite recrudescenceNotesLocation: University College Hospital, Ibadan, Nigeria\
Transmission: unknown\
Funding: World Bank/UNDP/WHO Special Fund for Research and Training in Tropical Diseases (TDR)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom numbers used.Allocation concealment (selection bias)Low risk\"Each child was then assigned a random number from a list prepared by an independent collaborator and thus allocated at random to receive either intramuscular artemether or intravenous quinine\".Blinding (performance bias and detection bias)   Objective outcome: DeathLow riskAn open‐label trial is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias)   Subjective outcomes: OthersHigh risk\"This was a randomized, open, controlled study in which no attempt was made to 'blind' the investigators, as the test drug and the control drug were given by 2 different routes\".Incomplete outcome data (attrition bias)   All outcomesLow riskOnly 1 patient excluded from fever clearance time outcome assessment because of urinary tract infection.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.

Characteristics of excluded studies \[ordered by study ID\] {#CD010678-sec-0127}
===========================================================

StudyReason for exclusion[Aceng 2005](#CD010678-bbs2-0020){ref-type="ref-list"}Intervention was rectal artemisinin.[Bhattacharya 1997](#CD010678-bbs2-0021){ref-type="ref-list"}Not an RCT.[Bunnag 1992](#CD010678-bbs2-0022){ref-type="ref-list"}Drug‐resistant malaria not severe malaria.[Dunyo 2011](#CD010678-bbs2-0023){ref-type="ref-list"}Uncomplicated malaria.[Falade 2007](#CD010678-bbs2-0024){ref-type="ref-list"}Comparison not parenteral treatment.[Fargier 1999](#CD010678-bbs2-0025){ref-type="ref-list"}Not an RCT.[Karbwang 1994](#CD010678-bbs2-0026){ref-type="ref-list"}Comparison not parenteral treatment.[Karunajeewa 2006](#CD010678-bbs2-0027){ref-type="ref-list"}Not an RCT.[Myint 1987](#CD010678-bbs2-0028){ref-type="ref-list"}Not an RCT.[Osonuga 2006](#CD010678-bbs2-0029){ref-type="ref-list"}No desired review outcomes.[Reham 2012](#CD010678-bbs2-0030){ref-type="ref-list"}Patients not randomly selected (non‐probability consecutive sampling used).[Rehman 2013](#CD010678-bbs2-0031){ref-type="ref-list"}Design is a case‐control prospective study.[Shwe 1988](#CD010678-bbs2-0032){ref-type="ref-list"}Not an RCT.[Shwe 1992](#CD010678-bbs2-0033){ref-type="ref-list"}Participants in the artemether arm also received single dose of mefloquine.[White 1992](#CD010678-bbs2-0034){ref-type="ref-list"}Participants not randomized.[^1]

Characteristics of studies awaiting assessment \[ordered by study ID\] {#CD010678-sec-0128}
======================================================================

[Danis 1996](#CD010678-bbs2-0035){ref-type="ref-list"}MethodsMulticentre trialParticipantsInformation not availableInterventionsInformation not availableOutcomesInformation not availableNotesInformation not available[Faiz 2001](#CD010678-bbs2-0036){ref-type="ref-list"}MethodsRCTParticipants105 adults enrolledInterventionsInformation not availableOutcomesInformation not availableNotesInformation not available[^2]

In the protocol, we specified that we would include only trials in children (aged \< 15 years) ([Esu 2013](#CD010678-bbs2-0072){ref-type="ref-list"}). However, we amended the inclusion criteria to include trials in adults and children.

We planned to explore data by drug regimen, type of severe malaria (cerebral versus non‐cerebral malaria), time since admission to hospital, length of follow‐up, and geographical region, but data were insufficient.

Dr Amirhaobu Uwaoma stepped down from the review author team.

Ekpereonne Esu (EE) and Emmanuel E Effa (EEE) identified and extracted data from eligible trials for this review. EE entered data into Review Manager 5 ([Review Manager 2014](#CD010678-bbs2-0062){ref-type="ref-list"}). EEE and EE performed 'Risk of bias\' assessments and analysed data. EE prepared the 'Summary of findings\' tables and the first draft of the review. All authors read, gave input to all sections, and approved the final version.

Internal sources {#CD010678-sec-0122}
================

University of Calabar, Nigeria.Liverpool School of Tropical Medicine, UK.

External sources {#CD010678-sec-0123}
================

Department for International Development, UK.Project number: 300342‐104

EE has no known conflicts of interest.  EEE has no known conflicts of interest.  OO has no known conflicts of interest.  MM has no known conflicts of interest.

[^1]: Abbreviations: RCT: randomized controlled trial.

[^2]: Abbreviations: RCT: randomized controlled trial.
